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In the healthcare domain, new processing techniques and new drugs are being 
developed continuously in order to make health care evolve for the comfort 
of patients. These developments also permit to discover better ways to treat 
commo11 diseases , but ahove all , to compete with the more rl.ifficult illuesses to 
eliminate. Clinical studies, as well internal in hospitals as sponsored by phar-
maceutical companies or authorities, provide a way to develop such treatments. 
Unfortunately, this activity does not benefit yet enough today of the 
benefits of IT to automate the process of research, and even less used to 
collect, share and store medical knowledge in the world. 
In this report , a software for the monitoring of clinical studies will be pre-
sented to computerize the data related to such an activity. It will manage 
the creation, reading, modification and logical deletion of clinical studies in-
formation, patients being enrolled and examinations to be performed on them. 
In addition, the results of researches on the automatic submission of medical 
data to sponsors of clinical studies will be presented. These studies were based 
on works provided by the organization CDISC which offers standards, estab-
lished to support the acquisition, exchange, submission and archive of clinical 
research data and metadata. 























Dans le domaine médical, de nouvelles techniques de traitement et de 
nouveaux médicaments sont mis au point continuellement afin de faire évoluer 
les soins de santé, pour le confort des patients. Ces évolut ions permettent 
aussi de découvrir de meilleurs moyens de soigner les maladies courantes, mais 
sur tout de rivaliser avec les plus difficiles à éliminer. Les études cliniques, 
aussi bien internes aux hôpitaux que celles sponsorisées par des firmes ou 
autorités pharmaceutiques , permettent de mettre au point de tels traitements. 
Malheureusement , cette activité ne profite pas encore assez de nos jours 
des bienfaits de l'informatique afin d'automatiser le processus de recherche, 
moins encore utilisée pour collecter, partager et stocker les connaissances 
médicales dans le monde entier. 
Dans ce mémoire, un logiciel de suivi des études cliniques sera présenté 
afin d' informatis r les données liées à une telle activité. Il permettra de gérer 
la création, la lecture, la modification et la suppression logique des informa-
t ions concernant les essais cliniques, ainsi que les patients y étant inscrits et 
les examens à réaliser sur ceux-ci. De plus, les résultats de recherches sur la 
soumission automatique des données médicales vers les commanditaires des 
études cliniques seront présentés. Ces recherches ont été basées sur les travaux 
de l'organisation CDISC qui établit des standards pour supporter l'acquisition, 
l'échange, la soumission et l'archivage de données et méta-données sur les 
études cliniques. 
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• Clinical Study : a research study using human subjects to evaluate 
the effect of interventions or exposures on biomedical or health-related 
outcomes. The two types of clinical studies are interventional studies ( or 
clinical trials) and observational studies. 
• Clinical trial : a clinical study in which participants are assigned to 
receive one or more interventions ( or no intervention) so that researchers 
can evaluate the effects of the interventions on biomedical or health-
related outcomes. The assignments are determined by the study proto-
col. Participants may receive diagnostic , therapeutic, or other types of 
interventions. 
• Observational study : a clinical study in which participants identified 
as belonging to study groups are assessed for biomedical or health out-
comes. Participants may receive diagnostic, therapeutic , or other types 
of interventions, but the investigator does not assign participants to spe-
cific interventions ( as in an interventional study). 
• Nonclinical study : moment of research which begins before clinical 
studies and during which important feasibility, testing and drug safety 
data are collected. 
• Site : hospital, clinic or other medical center where the clinical studies 
take place. Different sites may work together when they participate in 
the same multi-site study . 
• Protocol : the written description of a clinical study. It includes the 
study's objectives, design, and methods. It may also include relevant 
scientific background and statistical information. 
• Placebo : inactive and harmless product used to compare the results of 
a drug or active treatrneut , aud studied to learn more about its effects. 
The placebo is used in clinical studies as one of many possible treatments. 
Since the patient and health professionals usually do not know which 
subject received placebo and which has not received, the observations 
made in the clinical study can be more honestly, since it reduces the 
excessive attention of those who received the new drug. 
• Arm : a group or subgroup of participants in a clinical study who 
receives specific interventions, or no intervention, according to the study 























• Arm type : a general description of the clinical study arm. It identifies 
the role of the intervention that participants will receive. Types of anns 
include Experimental, Active comparator, Placebo comparator , Sham 
comparator, and No intervention. 
• Experimental arm : a group of participants that receives the inter-
vention that is the focus of the study. 
• Active comparator arm : a group of participants that receives an 
intervention that is considered to be effective. 
• Placebo comparator arm : a group of participants that receives a 
placebo during a clinical study. 
• Sham comparator arm : a group of participants that receives a pro-
cedure or device that is made to be indistinguishable from the actual 
procedure or device being studied but does not contain active processes 
or components. 
• No intervention arm : a group of participants that does not receive 
any interventions during a clinical study. 
• Randomization : a strategy in which participants are assigned to arms 
of a clinical study by chance. 
• Food and Drug Administration (FDA) : an agency within the U.S. 
Department of Health and Human Services. FDA is responsible for pro-
tecting the public health by making sure that human and veterinary 
drugs, vaccines and other biological products, medical devices , the na-
tion 's food supply, cosmetics , dietary supplements, and products that 
give off radiation are safe, effective, and secure. 
• Eligibility criteria : the key standards that people who want to par-
ticipate in a clinical study must meet or the characteristics that they 
must have. These include inclusion criteria and exclusion criteria. For 
example, a study might only accept participants who are above or below 
certain ages. 
• Inclusion criteria : the factors ( or reasons) that allow a person to 
participate in a clinical study. 
• Exclusion criteria : the factors ( or reasons) that prevent a person from 






















• lnformed consent : a process in which researchers communicate with 
potential and enrolled participants about a clinical study. This is when 
researchers : 
1. provide all the important information about the study, so that po-
tential participants can decide whether to enrol ( or if enrolled, to 
continue participating); 
2. ensure that potential participants understand the risks and poten-
tial benefits of participating in the study, and the alternatives to 
the research being conducted; 
3. stress that enrolling in (and staying in) a clinical study is completely 
voluntary. Because giving consent to participate in research is not 
a contract, participants can leave a study at any time. 
The goal of the informed consent process is to protect participants. It 
begius wheu a poteutial participant first asks for information about a 
study and continues throughout the study until the study ends. The re-
searcher and potential participant have discussions that include answer-
ing the participant 's questions about the research. All the important 
information about the study must also be given to the potential partic-
ipant in a written document that is clear and easy to understand. This 
informed consent document is reviewed and approved by the human sub-
jects review board for a study before it is given to potential participants. 
Generally, a person must sign an informed consent document to enrol in 
a study. 
• Sponsor : person or institution that has initiated a clinical study. In 
most cases, a sponsor is a pharmaceutical company, but it may be hos-
pitals or research sites. 
• Results submission : the process of submitting and updating sum-
mary information about the results of a clinical study to a structured, 
public Web-based results database, such as the ClinicalStudies.gov or 
the sponsors results databases. 
• Investigator : a clinical study is often proposed to private doctors or 
hospitals that are generally used to participate in research. They are 
called investigators. They offer their patients to participate in a study. 
Therefore, the patient has no direct contact with the sponsor. At the 
hospital, the whole team is involved : doctors, pharmacists, technicians , 























investigator of a clinical study is the key person supervising the conduct 
of a clinical study at a study site. 
• Study nurse : person who co-supervised clinical studies in the study 
sites. The study nurse is in charge of checking the controlled and moni-
tored conducting of the study. 
• Eudract number : EudraCT (European Union Drug Regulating Au-
thorities Clinical Studies) is the European Clinical Studies storage of all 
clinical studies of prospective medicinal products. A study is counted in 
the database if at least of the investigating site is in the European Union. 
This number is an identifier in documents relate<l to the stu<lies. 
• Pharmacokinetic (ADME) : studies the fate of an active substance 
contained in a drug after its administration in the body. It includes four 
major steps : absorption (A); distribution (D) ; metabolization (M) and 
excretion of the active ingredient and its metabolites (E). 
• Pharmacovigilance (Drug Safety) : activity of recording and evalu-
ating sicle effect re ulting from th use of drugs. 
• Adverse event : an unfavourable change in the health of a participant, 
including abnormal laboratory findings that happens during a clinical 
study or within a certain time period after the study is over . This may 
or may not be caused by the intervention being studied. 
• Enterprise JavaBeans (EJB) : server-side architecture of software 
components for the development in Java EE platform. The architecture 
proposes a framework to create distributed components stored on an 
application erver which permits to represent data ( entities) , to offer 
services with state or not between the calls (sessions) or to accomplish 
























1 Problem statement & motivations 
Today, advances in medicine become more important and numerous. Whether 
for discovering new drugs or medical procedures to improve existing tech-
nologies or to treat yet incurable diseases, research is conducted continuously 
throughout the world. These clinical studies are conducted initially on labo-
ratory cell cultures and then on animals. Once the processes are convincing 
and safe, it is necessary to realize these studies on humans to test their 
ptfectiveuess aud the etfects upou the hurnau hody; a uecpssary step heforp 
finding the new drugs and devices to the pharmacy, the doctor or the hospital. 
However, the activity is still young and does not yet use IT and their 
benefits to support the administrative management of clinical studies and the 
sharing of knowledge between the different countries. Indeed, in most cases, 
these studies are performed on patients and the collection of test results are 
generally achieved on paper. This is the job of the study nurse to realize such 
a tedious and repetitive task. Next , the data managers store the data in files 
who fil l the final records and sheets with the results. Sometirnes au iuternal 
or external person shall check the insertion of the results in the documents. 
These supports are then returned to the sponsor of the clinical study to 
inform him of the results of the clinical study and to judge the effectiveness 
of the drug or material tested. 
In this way, we understand this approach does not keep good track of 
previous clinical studies, and permits even less to analyse and share the 
results. The objective of the internship was to fill this gap in the domain of 























management of these clinical studies, to store and manipulate the correspond-
ing data. Therefore it would be possible for the different actors playing a role 
in the study process to participate in the successful storage of information, 
but also in a much larger project : the computerization of the management 
process and analysis of the data about clinical studies. Such an objective 
would not only keep track of all previous data, but will also permits to share, 
submit the data to the sponsors and authorities and analyse all information 
to finally make the health care evolve in the best way. 
The project took place to meet this objective by implementing a software 
to support the administration of clinical studies in hospitals , but which also 
provides tools to assist the analysis of study data. The project has been divided 
into two main parts : the administrative management of clinical studies and 
the system of analysis of test results. 
2 IFlec 
Following the request of Professer Thierry Vander Borght from the hospital of 
Mont Godinne, combined with the interest of the CHU of Liege, the Cwality 
2013 project, funded by the Walloon Region has started with objective to 
implement the project IFlec . MIMS has been declared as promoter of this 
project, working in partnership with the UNamur. 
The project aims to develop a module for managing clinical studies, 
integrated in OmniPro, a suite of stand-alone modules that cover various 
areas in hospitals. The module is implemented to be deployed in healthcare 
institutions to support the administrative management of clinical studies, 
and the scientific analysis of the data that these studies deal with. Thus, the 
module is divided into two main components that meet the two objectives 
of the project , and is implemented as the OP'Study module, a component of 
OmniPro. 
For my internship, the objective was to implement the first component 
concerning the administrative management of clinical studies. The project 
was then taken over by the company and by the UNamur to achieve the second 
sub-module. The project was estimated for a period of two years under the su-
pervision of Frederic Robinet of MIMS and Pierre Yves Schobbens of UNamur. 























: the prospective and the retrospective studies. Prospective studies are funded 
by a firm (e.g., pharmaceutical). or by the hospital itself for an internal project; 
bath cases with an objective set before the start of the study. Therefore, it 
is necessary that a protocol has been written to describe and defin th clin-
ical study in its entirety ( cost, progress, timing, number of patients required 
and numb r of sites, ... ). Retrosp ctive studies are research studies in the 
context of common diseases by analysing the data collected earlier; they have 
no predefined goal. During my intern hip , the focus was placed on pro pec-
tive clinical studies, with the use of the protocols information to describe the 
establishment and the monitoring of such studies. 
3 Thesis limits 
:\!Iy contribution to th IFlec project was to develop the first module to 
support the administrative management of clinical studies in hospitals. It was 
necessary for me to analyse existing sources, but mainly to meet the future 
users to clearly define the scope of the component to develop. Therefore, it 
has been possible for me to create the software in the allotted time, while 
interesting closer to a more specific tapie of re earch concerning the automatic 
submission of clinical study results to the authorities and sponsors of studies. 
However , it is important to note that the internship was carried out 
m Belgium, in a company developing computer software to support the 
management of patients in Belgian hospitals. My scope has been greatly 
reduced since it was therefore just targeted on Belgian hospitals, in particular, 
to the hospital of Mont-Godinne. Although the scope was reduced, wider 
requiremeuts aual_vsis was couducted iu differeut sites aud iu other ·ourœs 
to achieve a more generic software, rather than just focused on Mont-Godinne. 
The component to support the administrative management of clinical stud-
ies was conducted according to the objectives and requirements laid down, but 
could not be completed , however due to a delay in the development of a 
technology required to achieve a task. Indeed, the client had expressed his en-
thusiasm for making a schedule for clinical studies containing the examinations 
of all patients enrolled in a study. This schedule should provide different views 
for the users to have an overview of the daily, weekly, or monthly examinations 
of the patients related to a clinical study in particular. However, the delay in 
the implementation of a technology in the company blocked the development 























4 Persona! contribution 
Alongside the development of the module component to support the admin-
istrative management of clinical studies in hospitals, researches have been 
clone on an interesting field that still poses problems in the domain of clinical 
studies , concerning the automatic submission of clinical study results to t he 
sponsors of t hese studies. 
Submission of data related to examinations of clinical study is nowadays 
transmitted to the authori ties and sponsors via computer files or paper 
documents, customized for the clinical study. However , these supports are not 
often machine-readable, and therefore require several persans to deal with, 
uot only to fill thern i11 the sites fo r the submissio11 , but also to a11alyse thern 
at the sponsor sicle upon receipt . 
T herefore a research topic has been launched to find a possible solution 
to this gap in t he submission of clinical studies examinations results. To this 
end, a research question has been e tablished to guide the analysis : "Is it 
possible to find standards or international protocols that allow automatic 
submission of clinical study resul ts to the sporn;ors of these studies?" The 
question is very open and extending internationally, allowing us to see further 
a11d a11alyse the existi11g i11formatiou worldwide i11 this fie ld. 
Therefore we are fo cused in CDISC international organization, which offers 
standards established to support the acquisit ion, exchange, submission and 
archive of clinical research dat a and metadata. Analyses of these standards, 
and the results will be discussed later in this report. 
5 Thesis structure 
T his report includes the description of the analysis and results, both for the 
creation of t he module component for the administrative management of 
clinical studies, and for the research concerning the automatic submission of 
clinical studies results to sponsors. 
Firstly, a t heoretical chapter will be presented in order to present the 
r.urrent kuowledge about the two main dmuaiu · ideut ified iu this report. 
First, a general definition of clinical studies will be proposed in order to 























Belgium. Second, the organization CDISC will be described according to its 
standards available on their website. Such knowledge helps to understand the 
proœ88 of creatiug tabular files for the 8ubnli8siou of cliuical 8tudy re8ult8 to 
sponsors and authorities. 
Then, an introduction to the infrastructure established in the company 
MIMS will be presented, especially in the cell of Java development. VIe firstly 
discuss the different technologies used in the cell for the development of 
modules. Then we will introduce the technical aspect of the infrastructure in 
two parts : the internal structure of the Java cell to explain the use of work-
stations, the connection to servers and the SVN and continuous integration 
systems. Finally, a comprehensive presentation of the central database of the 
company will be given in order to understand the data structures with which 
it was necessary to work for the development of the new module. 
The next two chapters respectively present my research and findings, on 
the one hand in developing the components of the OP'Study module, and 
on the other hand, in the search of an international standard for automated 
submissiou of exarniuatious result8 related to cliuical studies. The fi.rst part 
will introduce the methodology used to develop such a software and the 
various technical parts of the development, namely the database and the 
implementation. The second part offers examples to understand the creation 
of tabular files for the submission of data to the sponsors, and a summary of 
results with a short cri t ics section concerning the standards of the organization 
CDISC. 
The last part of this report will introduce the future objectives of the IFlec 
projed , both for the coutiuuatiou of the first mo<lule for the a<lmiui8trative 
management of clinical studies in hospitals, and for the second component 
concerniug the scientific aaalysis of the results of these studies. This chapter 
will also offer recommendations for the automatic submission of clinical studies 
























State of the art 
1 Clinical studies 
1.1 P resentation 
Clinical studies are research studies on human subjects, supervised by an 
investigator , which can be of two types : interventional or observational 
studies. Therefore, they are realized to give responses to specific questions 
concerning biomedical or behavioral interventions such as new vaccines, drugs, 
treatments, functional foods , dietary supplements, devices or new ways of 
using known interventions. Such studies permit to generate safe and efficient 
data to meet the ever changing needs in health care, making new medicines 
and devices available to the general public and to caregivers. 
However, before a drug reaches the phase of clinical studies, it is thoroughly 
tested through a basic or preclinical laboratory research in both laboratory 
experiments (in-vitro, i.e. on cell cultures) and on animals (in-vivo). The 
type of experiment depends on the disease being studied and whether there 
is a good animal model of the disease. This type of research is extremely 
important to gather information about the benefits and potential limitations 
of the drug before it is tested on humans. 
The new drugs are then tested on humans during clinical studies, also 
called clinical pharmacology studies. They provide valuable information such 
as the amount of drug administered and the frequency of administration, as 
well as how the new drug is tolerated. 
Before the beginning of the clinical study, satisfactory information need to 























according to the country where the approval of the therapy is sought. To 
participate in a study, patients must meet very specific criteria. It permits to 
select the subjects for which the study treatment is best suited, and to exclude 
those for whom treatment is not indicated. Next, and depending on product 
type and development stage, investigators initially need to enrol volunteers 
and/or patients into small pilot studies, before realizing progressively larger 
comparative studies. In general, the safer and the more effective are the data 
collected, the more the number of patients enrolled increases. Obviously, the 
size of the studies may change, and may occur in only one site or more, or 
in one or more countries. The clata gathered from d inical atudies are finally 
submitted to sponsors to analyse the results and to pursue the research process. 
It is important to understand that both the basic research and research 
through clinical studies are carefully supervised, monitored and documented. 
New drugs must be blameless and without suspicion before sitting on the 
shelf in the pharmacy. 
However, it is important to notice that there exist two types of clinical 
stud.ies, the most commou studies are prospective, as clefiued above, wheu 
the protocol information and the objective of the study are clearly set before 
its beginning. Therefore, the population to be studied with the inclusion and 
exclusion criteria are defined, but also the parameters to be studied and the 
study output criteria. The second type concerns retrospective studies. They 
focus on the research of links between health data collected in the past , but 
their objective are not a priori defined. It is based on the exploitation of 
documents whose reliability can not be guaranteed and exposed to selection 
bias. All the events, latent period and subsequent outcome ( e.g. development 
of disease) have already occurred in the past. Data are merely collected at 
the present moment , and the results are not used to establish the risk of 
developing a disease if the patient is exposed to a particular risk factor. 
The process of retrospective clinical studies is much more different relative 
to the activities realized for prospective studies. In the case of a retrospective 
study, data are collected from past records concerning patients medical 
history or lifestyle by the investigator. Furthermore, such studies do not 
follow patients medical monitoring as is the case for prospective studies. The 
last are conducted by beginning the study with the establishment of two 
groups ( e.g., exposed versus non-exposed to the new drug) at the current 
























occurrence of disease, if any. 
The methodology of prospective and retrospective studies is funda-
mentally the same, but the last is realized a posteriori. The process to 
complete a retrospective study is as long as it takes to gather, analyse 
and interpret the data. Therefore, such studies are made to examine possi-
ble risks related to a result that is already known at the beginning of the study. 
Clinical studies are a mandatory and systematic stage of the drug develop-
ment . In thet1e t1tudiet1 t1teµ, there are 4 different µhat1et1 : 
• Phase I : during this phase, tests are generally conducted on healthy 
volunteers. These tests are conducted in specialized sites that have re-
ceived approval from the health authorities to realize such studies. These 
studies have two major objectives. First, it is to ensure that the toxicity 
results obtained during pre-clinical development, are comparable to those 
obtained on humans. It helps determine what is the maximum dose of 
the drug tolerated on humans. Second, it is to measure, using pharma-
cokinetic studies, the fate of the drug in the body according to its mode 
of administration (absorption, distribution, metabolism and excretion). 
• Phase II : the Phase II studies are designed to determine the optimal 
dosage of the product in tenns of safety and efficiency in a limited and ho-
mogeneous population of patients, about several hundred persons. Drug 
interactions and pharmacokinetics are sometimes studied at this early 
stage. 
• Phase III : these larger tests are conducted on several thousand pa-
tients who are representative for the population targeted by the treat-
ment. They are comparative tests in which the drug is compared to 
an effective treatment already marketed or, in some studies, a placebo. 
This comparison is most often, double-blind and draw. The treatments 
are randomly assigned, and the patient and the doctor in charge of the 
monitoring are aware of which treatment is administered. These tests 
are intended to demonstrate the therapeutic value of the drug and to 
evaluate its be11efit/ risk ratio. It is at the end of Phase III that the re-
sults can be submitted, for example, to the European Health Authorities 
(EMEA) for obtaining Marketing Authorization (MA). 
• Phase IV : the Phase IV studies are conducted after a drug has been 
marketed , often on a very large number of patients (up to tens of thou-























actual use conditions and evaluate large-scale tolerance. Pharmacovigi-
lance can detect rare sicle effects that have not been highlighted in the 
other test phases. 
Clinical studies in Belgium are regulated by the law concerning experiments 
on the human person (7 May 2004: Act concerning experiments on the human 
person). This law structures the tests and regulates the conditions for the 
Protection of Persans who are suitable for research to develop drugs or medical 
therapies. It specifies the requirernents for the sponsor of cliuical studies : 
• The obligation to deliver clear and complete information to the person 
so that he can make his written consent in a free and informed manner. 
• The mandatory pre-submission of the study protocol to the Ethics Com-
mittee. This independent committee evaluates the value of the test for 
patients, potential risks, precautions taken, and clarity of the information 
to the patient. 
• The subscription by the sponsor of an insurance. This mandatory war-
ranty insurance covers damage related to the research throughout the 
duration of the test but also during a period of 10 years following the 
end of the study. 
• The free provisions by the sponsor of all medications. 
• Financial support of supplies and examinations specifically required by 
the protocol. The protocol must be submitted to the Federal Agency 
for Mediciues aud Health Products ( AFP MS), which verifies that all 
the measures to ensure the safety of those involved in clinical studies 
are taken. The AFMPS gives or not the permission and, if permitted, 
follows the studies processes. 
Furthermore, IY\edical data collected from patients being tested are stored in 
computer files that will be analysed by the sponsor to assess the beuefit of 
treatment . Under the Data Protection Act, the patients may at any time 
exercise their rights of access and correction of their data by contacting their 
doctor. 
1. 2 Actors and roles 
In Belgium, several type of persans are concerned in the establishment and in 
the management of clinical studies processes. According to the information 























groups of persons : the internal staff of the site, and other intermediate. 
In the one hand, the internai persons are represented in 2 sub-groups 
the site staff and the patients. The first group consists in different services 
and persons, namely the accounting service which manages and assigns the 
bills to the sponsors or to the patients, the principal service in which the 
clinical study has been established, plus the secondary services in which the 
study is realized ( e.g., hematology, radiology, ... ) . It contains also one local 
Ethics Committee to locally negotiate the establishment of the clinical study 
in the site according to its feasibility and the fact that the patients meet the 
criteria. Furthermore, the internal staff includes the principal investigator 
which is responsible of the management of the study, the possible other 
investigators of clinical studies ( often doctors) , study nurses who monitor 
patients examinations and their results and data managers for the gathering 
of clinical studies results data. 
In the second hand, different intermediate play a role in the establishment 
and in the monitoring of clinical studies. Firstly, the sponsor (pharmaceutical 
agency, research institution, or governmental organisation) is the initiator of 
clinical studies, it directly communicates with a clinical research organization 
(CRO) which makes the liuk hetweeu the sponsor aud the differeut sites. The 
CRO manages the contracts between the hospitals and the sponsors. There 
exist independent local Ethics Committees in the sites participating in the 
same clinical study. Each opinion of these committees is essential to advise 
the central Ethics Committee in charge of the monitoring of the clinical study 
and its clefinitive approbation. 
In summary, the initiative to launch a clinical study cornes initially from a 
sponsor. Often, it does not communicate directly with the hospital but with 
a clinical research organization ( CRO) . The last is therefore the link between 
the clinics and the sponsor. To prepare a study within the hospital, the CRO 
communicates with the service in charge of the study in order to negotiate 
on its feasibility. When the service tends towards accepting to participate 
in the study, it submits the protocol of the study to the Ethics Committee 
for approval. The local Ethics Committee must transmit information to the 
elected central Ethics Committee which has the final word to approve the 
c.liuical studies ou the differeut sites. If the agreement is doue, the study starts 
























1.3 Clinical studies monitoring 
To introduce and explain a prospective clinical study, sponsors have to provide 
a protocol which explains the entire study, from the pre-treatment up to the 
fo llow-up of the patients after the treatment. This document contains several 
types of information , concerning each phase of the study process. From these 
texts, the authorities in charge of the management of these studies and t he 
corresponding hospitals gather information t o establish and realize safely and 
comprehensively the clinical studies in the sites. 
According to tieveral tiourceti from different tiiteti in Belgium, the etitablitih-
ment of clinical studies consists in 8 main stages. The global process in divided 
iu differeut maiu activitieti, reali7.ed iu a logical tüne order. 
Figure 2.1: The eight main activities in the process to establish and monitor 
a clinical study. 
• Feasibility questionnaire : the CRO is the authority between the 
clinics and the sponsors. To establish a new study, the designated CRO 
communicates with the service in charge of the future clinical study to 
estimate its feasibility. If the study needs more t han one site for its 
realization, the CRO gather answers from the different clinics and the 
corresponding services to decide of the feasibility of the study according 
to its necessary criteria to be established. 
• Local Ethics Committee : the local Ethics Committee of the corre-























in the t:iite. To accomplit:ih thio tat:ik, the authority firnt checkt:i that pa-
tient compliance and health are ensured. Then it checks if the service 
concerned by the study is able to conduct the study according to the 
requirements. To this end, it may also establish its own questionnaire 
and ask questions of the investigator in charge of the study. Once the 
study is approved by the central Ethics Committee, the local authority 
shall assign a number identifying the study in the site. 
• Central Ethics Committee : the central Ethics Committee is ap-
pointed by the sponsor and the CRO to gather the opinions of the var-
ions local Committees. It negotiates arrangements with the sponsor to 
estimate the time required for the process , the total number of patients 
to be included in the study and all other requirements necessary for the 
successful completion of the study. The central Committee finally de-
cides if the establishment of the study in the sites is approved, but also 
decides the introduction of changes relative to study protocols. 
• Training of the site : the hospital is trained to prepare the study and 
its correct and complete realization. The various examinations, medica-
tions, and data sheets are prepared to gather data before, during and 
after treatment. 
• Patients enrolment by the investigator : the investigator enrols 
patients in the study according to the inclusion and exclusion criteria 
contained in the study protocol. He shall also send to potential patients a 
contract in which they give their informed consent , and provide informa-
tion about the study such as side effects, advantages and disadvantages , 
• Screening : activity during which varions tests are performed on pa-
tients enrolled to ensure that the patients meet the criteria, but also to 
measure the values of patients before treatment. 
• Randomization : statistical equilibrium for sharing patients between 
treatment options provided by the protocol of the clinical study. For 
example, one of three patients will receive a placebo treatment, another 
a treatment with a low dose medicine and the latter with a higher dosage. 
• Treatment : activity during which the molecule or process to be tested 
is applied to registered patients. According to the study, the treatment 























In the protocol provided by the sponsors, information is introduced to explain 
the different stages of the treatment activity. According to the objectives 
of such studies, the treatment can take place in several cycles during which 
examinations are realized on patients to gather the data resulting from the 
administration of the molecule tested or the use of a new device, according to 
the clinical study objective. 
Therefore, the protocol provides the information about the activities to 
realize during each phase of the clinical study, namely the screening, the 
treatment and the follow- up (post-treatment). 
Other important external activities are realized during clinical studies. For 
example, the monitoring and the submission of data. Data managers are in 
charge of gathering the results of the studies to store them in different files for 
the submission to the sponsors. It is possible, during and after the collection 
of data, that an internal or external person (sponsor) checks the integrity and 
the validity of the data stored for the submission of the results to the sponsors. 
2 CDISC 
We have focused on the monitoring of a clinical study. In 2014, the total 
number of clinical studies registered on ClinicalTrials.gov indicated 159 327 
interventional and observational studies. These studies permit to make the 
health care evolve, but it is even more interesting for all researchers and 
clinicians to be involved in an even larger project: the sharing of medical 
information and research results. To this end, various organizations around 
the Earth have attempted to establish standards and protocols which they 
offer to different hospitals to structure computerized clinical studies and most 
importantly, to collect and share data relevant to the knowledge exchange 
between different sites. The use of such standards allows a more accurate 
and comprehensive analysis of the evolution of healthcare by collecting all the 
data in larger organizations that bring together the knowledge to analyse, do 
statistics, but also share knowledge about the health care. 
We focused here on CDISC (Clinical Data Interchange Standards 
Consortium) , an international organization that provides standards for each 
phase concerned in conducting clinical studies, ranging from data collection 
to the submission and analysis of such information. CDISC, through its 






















sponsors of the studies. 
2.1 Presentation 
"CDISC is a global, open, multidisciplinary, non-profit organization that has 
established standards to support the acquisition, exchange, submission and 
archive of clinical research data and metadata. The set of standards has been, 
and will continue to be, developed to support the streamlining of processes 
within medical research from the production of clinical research protocols 
through to reporting and/or regulatory submission, warehouse population 
and/or archive and post-marketing studies/safety surveillance. The CDISC 
mission is to develop and support global, platform-independent data standards 
that enable information system interoperability to improve medical research 
and related areas of healthcare"[6]. CDISC standards are vendor-neutral, 
platform-independent and freely available via the CDISC website. 
Nowadays, proprietary and personalized standards are used all around 
the globe to gather, archive and analyse data and metadata in hospitals. 
This approach does not allow information interchange, which is however 
the most essential activity to make international partners work together to 
exchange data among clinicians and researchers. Clinical care can collect 
benefits through clinical studies findings, and clinicians will be interested in 
participating in studies if the research process can be simplified by integrating 
it into their clinical care workflow. Therefore CDISC offers the possibility to 
adopt its global standards for clinical studies, which should continue to be 
harmonized with healthcare standards, to provide a means for interoperability 
among healthcare and research systems such that medical research can 
support informed healthcare decisions and improve patient safety. 
2.2 Clinical studies protocols 
To introduce a clinical study, sponsors introduce study protocols. A study 
protocol ü; a plan for executing a study. The first interesting part of that plan 
is the design of the study. CDISC uses the tenn study design which contains : 
• The experimental design of the study. A study subject can be 
assigned to different arms in a clinical stucly. The experimental design 
specifies, for each of these anns, the set of treatment strategies that the 
subject will follow. A strategy is to be interpreted widely to include 
preparation for treatment, non-treatment , placebo treatment, retraction 























• The schedule of activities for the study. The schedule includes 
planned visits or other times during which treatments and assessments 
are to be done. It also contains other activities to be performed and the 
plans for which activities are to be done at which times. The scheduling 
depeuds ou differeut subject couditious (suhject is female, subject has 
experienced a certain adverse event or had an abnormal lab result , ... ). 
• The eligibility criteria for the study. 
• Certain summary information about a study. The summary con-
sists in information such as its title, study phase, objectives, sex, age, 
and other characteristics about eligible subjects, but also the number of 
subjects, and planned duration. 
CDISC standards represent different aspects of this study design : 
• The Operational Data Model (ODM) . ODM represents metadata 
for the data collected in a study. Soit is closely aligned with the schedule 
of activities, even if it does not describe the planned timing of the set of 
data called study events, which generally represent the data collected at 
visits. 
• The Study Data Tabulation Model (SDTM) . It includes study 
design datasets which represent different information : ummary infor-
mation, eligibility criteria, the experimental design and planned visits. 
These datasets do not include planned activities or times other than 
those designated as visits. So datasets do not describe the full schedule 
of activities. 
• The Protocol Representation Model (PRM) . PRM is a conceptual 
model, documented in UML, of the concepts of a clinical study protocol. 
It includes all concepts of the study de ign, as defined above. 
These staw lards are deeper defiuecl be low. 
Typical protocol documents are not in a useful format for information col-
lection and re-use. Nowadays, the standardization consists often in a machine-
unreadable Word Document with a simple use of police size and font to bring 
out important information. With the PR 1 and is pred fined set of variables 
representing all types of information contained in the studies protocols, it is 
easier for the users to extract information to : 
























• Enrol the study into study registries and other study tracking systems; 
• Create case report forms (CRF) using the CDISC standards; 
• Bring important information into CDISC Operational Data Model 
(ODM) or similar format for data collection (e.g. eCRFs) and data 
archiving objectives. 
• Establish datasets for electronic submission of the clinical studies infor-
mation to the differeut authorit ies aud sponsors. These datasets eau 
contain all types of data concerning clinical studies; 
• Re-use of protocol information in the final clinical study report. 
It is highly time-consuming for the protocol's users to use processes to extract 
and re-use protocol information as few of these are automated. In addition, 
users need only just a small part of the information in the typical 60-80 
pages of the protocol document , making the document heavy to read and to 
interpret. Ensuring that all clinical research protocols meet a minimal set 
of requirements and provides tagged information that is machine-readable 
permits to re-use and re-display automatically this information in different 
forms. For instance, the study design can be summarized in a form that is 
easily understood by reviewers, promoting a more efficient and higher quality 
review. CDISC PRM is the foundation for such a machine-readable protocol. 
The protocol is the core to every clinical studies. So PRM was developed 
to represent that core and to hold the most critical pieces of information 
in a machine-readable format. PRM effectively standardizes the content 
of the protocols : it contains a large set of some 300 standard concepts 
concerning the study objective and its monitoring. These concepts are to 
be represented and structured to make the resulting document easy to read 
and understand for a researcher, but also permitting an easy exchange of 
protocol information between systems. Furthermore, the data contained in 
the protocols are re-usable in multiple ways without re-entry. The PRM 
concepts are typical across study protocols, but they do not reflect either a 
minimum or a maximum set of elements. 
In addition, it is possible to generate a protocol from the compo-
nents of the PRM that is human-readable for users of the document. So the 
time consumed and the costs are reduced. 
PRM is a support for different important clinical studies objectives : increas-























m studies, a<lhering to study registry requirements, filling study manage-
ment/tracking systems , providing authorities with clinical studies protocols 
information, writing post-study reports, ... 
The major areas of clinical studies protocols are represented in the 
PRM elements : the clinical study registry, the eligibility criteria and the 
study design. The protocol is used in designing the study, selecting inves-
tigative sites, developing the data collection tools, and describing the study 
procedures and the analysis plan. 
2.3 Collection and submission of clinical studies data 
Concerning the data collected during clinical studies, CDISC introduces the 
Study Data Tabulation Moclel (SDTM) standard. SDTM defines a standanl 
structure for study data tabulations that are to be submitted to a regulatory 
authority such as the sponsor of a study. SDTM includes datasets which 
represent the summary information, the eligibility criteria , the experimental 
design, and the planned visits of a clinical study. However, no datasets for 
planned activities or times other than those designated as visits are introduced 
by the standard. So SDTM do not represent the full schedule of activities 
of the study design. The model is still evolving to represent new kind of 
studies on humans and animals : food additives , therapeutic biologies, blood 
derivatives , vaccines, cellular, tissue, and gene therapy, and devices. 
CDISC introduces implementation guides for applying the model to each type 
of data. Sorne of these guides are under development and others are already 
used and freely available. 
The submission of data to regulatory reviewers provides benefits : 
• Reviewers can be trained to use the standard software tools and the 
standardized datasets. Therefore, they need less training time to work 
efficiently with the data. 
• Thanks to datasets, regulatory authorities such as FDA can develop 
repositories for the submitted studies and different tools to access , ma-
nipulate, view the studies data. 
SDTM provides a general framework to describe the structuring of information 
collected during studies and submitted to regulatory authorities. The model 
is built around the concept of observations, which consist of discrete pieces of 























in a dataset and a collection of observations on a particular topic is considered 
as a domain. Named variables are introduced to describe these observations. 
They correspond to a column in a dataset. F\irthermore, each variable 
is classified according to its role which describes the type of information 
communicated by the variable and how it can be used. The SDTM describes 
the name, label, role, and type for the standard variables. Data collected 
in a study is about the humans or animals who are enrolled in the study. 
Other information can be collected to represent the data about other persons 
(Associated Persons domain for example) who are bound with the study or 
with a study subject, a device used in a study, ... The observations made 
about study subjects are collected in series of domains for all the subjects. 
These domains represent a collection of logically related observations with a 
common theme. The relationship may belong to the scientific subject matter 
of the data or to its role in the study. 
The datasets are represented in fiat files with rows representing ob-
servations and columns representing variables. To complete the data 
contained in the datasets , metadata definitions are provided to explain the 
variables used in the datasets. These metadata are introduced in a data 
definition document , named 'define.xml", which is submitted to the regulatory 
authorities with the datasets. For the submissions, sponsors can choose to 
drop certain variables, which are not useful for submission, from the datasets 
and from the Define-XML. One of the limitation of the variables provided 
by SDTM is the fact that sponsors must not add new variables or modify 
the existing ones. They have to refer to the right implementation guide to 
consult the list of existing variables and their description to know which ones 
are required, expected or permissible to use in specific domains. 
SDTM introduces three general observation classes for the majority of 
observations collected during clinical studies 
Findings. 
Interventions, Events and 
• The Interventions class concerns investigational, therapeutic and other 
treatments that are administered to the subjects. The interventions 
are either as specified by the study protocol or other substances self-
administered by the subjects like alcohol, tobacco, ... 
• The Events class concerns planned protocol steps : randomization and 
study completion. Furthermore, the class captures the occurrences, the 
























of planned study evaluations ( e.g., adverse events) or prior to the study 
(e.g. , medical history). 
• The Findings class concerns the observations which r sult from planned 
evaluations to adclr ::;s ::;pecific tests or questions : laboratory tests, ECG 
testing and questions listed on questionnaires for example. The class pro-
vi<lt>s also a sub-typt> "Fiu<liugs About" which is ust>d to collt>r.t fin<liugs 
bound to observations in the Interventions or Events classes. 
Many implementation guides exist for the SDTM. For example, CDISC intro-
duces SDTM Implementation Guide for Human Clinical Studies and the SE D 
(Standard for the Exchange of onclinical Data) Implementation Guide. It 
is important to remember that not all variables described in the SDTM are 
relevant for all implementations. The SDTM is designed to provide the widest 
range of human and animal study data in a standardized manner. The model 
introduces the basic concepts and the general structures of the model. Dif-
ferent individual implementation guides have been created to offer specific 
recommendations for domains of data often collected in human, animal and 
medical device studies; each guide introduces which variables of a general ob-
servation class may apply. These guides provide also basic assumptions and 
business rules and offer examples for mapping data to the standard format. 
I3efore the suhmis ·iou of <lata iu a staudar<lized format, spousor · should first 
consult the implementation guides before creating its regulatory submission 
based on the SDTM. 
2 .4 Other standards 
Thanks to PRM and SDTM, the submission to regulatory authorities and 
sponsors of protocol information and data collected during clinical studies is 
possible iu a more simple way. Furtliennore, ODM aucl Defiue-XML permit 
to add information about metadata bound to the data collected for the 
PRM and the SDTM respectively. However, CDISC introduces also other 
standards which concern each step of the clinical studies life-cycle. Clinical 
Data Acquisition Standards Harmonization (CDASH) and Laboratory Data 
Mo del (LAB) are standards concerning the data collection phase of clinical 
studies which will be used in SDTM. Standard for Exchange of onclinical 
Data (SEND) concerns the exchange of nonclinical data via data tabulations. 
Analysis Data Model (ADaM) is a standard to introduce statistical analyses 
performed on the clinical study results. Furthermore, CDISC provides 
standards to exchange data, based on XML technology : the Study Design 























The Clinical Data Acquisition Standards Harmonization (CDASH) 
standard defiues basic stawlanls for the collection of diuical stucly data. 
CDASH identifies the basic data collection fields ( or variables) needed from 
a clinical, scientific au<l regulatory perspective to permi t a more efficient 
and consistent data collection at the different ites where the studies take 
place. SDTM is related to CDASH, SDTM provides a standard for the 
submission of data and CDASH defines a basic set of highly recommended 
data collec tion fields that are present in the majority of CRFs and therefore 
is earlier in the data-flow. These fields can be mapµ ecl to the SDTM structure. 
The objective of CDASH is to off Pr au iustrumPut to stau<lardi7:P 
the structure of the data collected in the clinical studies. "There is arguably 
no more important document than the instrument that is used to acquire 
the data from the clinical study, with the exception of the protocol, which 
specifies the conduct of that study. The quali ty of the data collected relies 
first and foremost on the quali ty of that instrument. No matter how much 
t ime and effort go into conducting the study, if the correct data points were 
not collected , a meaningful analysis may not be possible. It follows, therefore, 
that the design, development and quality assurance of such an instrument 
must be giveu the u tmost atteution:' [38] . Therefore , The CDASH stau<lar<l 
introduces the basic recommended data collection fields for domains of data 
bound to clinical studies. These domains include common header fields, 
demographic, adverse events, and other safety domains that are common to 
all therapeutic areas and steps of clinical research. 
The Laboratory Data Model (LAB) objective is to develop a model 
to support an important CDISC activity. 
To respond to business requirements concerning industry priorities in the 
development of standard models to help in the interchange of clinical studies 
data, a survey took place. According to the results of the survey, it seemed 
to be essential for industry to prioritize on standards which facilitate the 
exchange of clinical laboratory data into central data management systems. 
Furthermore, it appeared also interesting to create standards that would 
facilita te the exchange of data from CROs to sponsors. 
Thereby, the LAB mission mission is the development of a standard 
model for the acquisition and interchange of laboratory data . The objective 























• Define requirements to improve laboratory data interchange. 
• Develop a standard content model to acquire and interchange clinical 
studies laboratory data. 
• Test the model with complex and real laboratory data to assure its func-
tiouali ty and efficiency. 
• Explore other opportunities to improve laboratory data processing with 
other standards. 
Therefore, LAB completes the range of domains covered by CDISC standards 
for the acquisition of clinical studies data. 
Standard for Exchange of Nonclinical Data (SEND) is a standard 
for the implementation of the SDTM for nonclinical studies. It consists 
in a way to offer nonclinical data in a consistent format via datasets for 
interchange between sponsors and CROs and for the submission to regulatory 
authorities. The data are collected in the pre-clinical phase of clinical studies. 
Datasets based on SDTM and SEND are used to support different 
objectives : 
• Develop a repository for all submitted study data. 
• Provide tools to access, query, and view the data in the datasets. 
So SDTM and SEND are bound and complementary in the sense that they 
both provide a model for the creation of datasets for clinical and nonclinical 
data. 
CDISC's Analysis Data Model (ADaM) specifies the fondamental 
principles and standards to create analysis datasets and bound metadata. It 
also supports efficient generation, replication and review of analysis results. 
The implementation guides introduce guidelines and rules to define and create 
ADaM datasets , and propose the validation of the structure and the content 
of the datasets via a subset of rules which are objective and evaluable. The 
validation checks are defined to be machine readable. 
CDISC also provides standards to exchange data, based on XML tech-























Study Design Model-XML (SDM-XML) permits to introduce machine-
readable and interchangeable descriptions of the design of clinical studies. 
It is au exte11sio11 of the OD 1 specificatiou, aud so, SDM-XML offers to 
implementers the ease of use of the existing ODM concepts and the re-use of 
ODM defiuitious. 
SDM-X:YIL is used by CDISC to define the study design of the clin-
ical studies protocols. It is important to add that a study design model is 
just a model of a study's design. It is not a record of an individual study 
µarticiµant in a stucly. The stucly design moclel elements are classifiecl into 
different global components which enable a structured representation of a 
clinical study's design : the protocol summary, the eligibility criteria, the 
structure (arms, activities, ... ), the workflow and the timing. 
As previously explained, Define-XML is a model that is used to de-
scribe SDTM, SEND and ADaM datasets to submit them to regulatory 
authorities, or sponsors. The model is based on the extensions to the ODM : 
the purpose is to comply with all applicable regulations. 
The first released version of Define-XML described the requirements 
for coustruchug clefi11e.xml documents to replace the clefiue.pclf documents 
which were recommended by the FDA's Regulatory Submissions in Electronic 
Format. Define-XML documents have then be used for the transmission of 
case report tabulation ( CRT) metadata. The format of the document brings 
one key benefit to the reviewers : it provides both a machine-readable format 
for software applications and, with the provision of an XSL stylesh et for 
example, a browser-based report which describes the contents of a clinical 
study. 
ODM offers a feature to defiue schema extensions to cornplete the 
model. Define-XML model is implemented as a set of extensions to ODM 

























In this chapter, the technologies used and the technical and data base infras-
tructures adopted by MIMS will be presented. It is important to notice that 
the internship took place in the Java cell of MIMS enterprise. This section only 
preseutr:, the infrastructure ur:,e<l iu that c:ell. Firntly, the differeut tedmologies 
used by the Java teams will be explained to understand the advantages of their 
use. Then, the technical infrastructure will be introduced : the internal in-
frastructure will be explained before the Java projects structure and the client 
view concerning the use of the OmniPro application. Afterwards , the database 
structure will be showed both in general and internally. To conclude, positive 
and negative critics about the infrastructure will be raised. 
1 Technologies 
This section will present the technologies most commonly used in the Java 
cell of the enterprise. The module OP'Study development consisted in the 
utilisation of these technologies based on the Java programming language. 
Maven, Spring, Hibernate and JavaFX will be introduced in the next sections. 
1.1 Maven 
Apache Maven is a tool to manage and automatize the production of Java soft-
ware products in general and Java EE in particular. The objective of the tool 
is comparable to Unix Make system, i.e . produce a software from his sources 
in optimizing the realized tasks and in guaranteeing the right fabricat ion order. 
Maven is similar to Ant tool but provides simpler configuration ways and 
is also based on XML format to describe the software project being built , 






















plug-ins. It is managed and was produced by the Apache Software Founda-
t ion organisation to simplify the build processes in the Jakarta Turbine project . 
Maven used the well-known Proj ect Object Model (POM) paradigm 
to describe a software project , his dependences with external modules and the 
tasks ordering for its production. It is available with predefined tasks such as 
the compilation of Java code or its modularisation. 
A key element relatively specific to Maven is its aptitude to work 
with network. A mean for the synchronisation of independent proj ects was 
the primary motivation for Maven creation : the st andardized publication 
of information and the automatic distribution of jar modules. Therefore, 
even in the basic version of Maven, it is possible for the tool to dynamically 
download in t he local cache some materials on known software repositories 
such as Maven 2 Central Repository. The local cache can be completed with 
art ifacts from local projects . So, Maven offers a transparent synchronisation 
of the necessary modules. 
Maven has a plugin-based architecture that permits to users writ-
ing plugins as a standard input to interface with Maven build tools : 
compilers, unit test tools, ... for any programming language. But in reality, 
programming languages, except J ava, didn 't benefit from any support and use. 
Maven version 1 and Maven version 2 were developed in parallel 























Maven proj ct8 are configured u ·ing a POM, which is stored in a pom.xml 
file. Here 's a minimal example : 
1 <?xml version="l.0" encoding="UTF-8 11 ?> 
2 <project xmlns="http://maven.apache.org/PDM/4 .0.0" 
3 xmlns :xsi="http://www.w3.org/2001/XMLSchema-instance" 
4 xsi:schemaLocation="http://maven.apache.org/POM/4.0.0 http : // 
maven.apache.org/xsd/maven-4.0.0 .xsd"> 
5 <! -- Model version is always 4 .0.0 for Maven 2 . x P0M files-- > 
6 <mode1Version>4.0 . 0</mode1Version> 
7 
s <! -- Project coordinates, i.e., a group of values which uniquely 
identify this project --> 
g <groupid>be.mims</groupid> 
10 <artifactid>op-study-view-javafx</artifactid> 
11 <version>l .0 .0-SNAPSH0T</version> 
12 
13 <! -- Parent module of the current project --> 
14 <parent> 
1s <groupid>be.mims</groupid> 
16 <art if actid>op-study</ art if actid> 
17 <version>l.0.0-SNAPSH0T</version> 
1s </ parent> 
19 
20 <!-- Library dependencies --> 
21 <dependencies> 
22 <dependency> 







The pom.xml file defines a unique identifier for the proj ect , called coordinates 
in the example, and its library dependencies , on the JavaFX (jfx-rt) framework 
here. Fur thermore , the parent of the project presented here is defined in the 
configuration file to bind the current module with it8 parent. So, the grouplD 
identifies the organization which creates the project , the artifactID introduces 
the name of the project or the module and the versionID contains the ver-
sion of the project. It is possible to know the state of the current project; 
Maven introduces two states : SNAPSHOT versions which are in development 
and RELEASE versions which are definitive and frozen. Furthermore, Maven 
provides default values for the configuration of the project , it realizes these 
operations automatically; this is the idea of Convention over Configuration, 
on which Maven is based. The directories structure of a basic and minimal 
Maven project has the following non-exhaustive list of repositories entries : 
• / src : project sources 























• /src/main/java : source code 
• / src/main/resources : re ·ources files (images, appendices files , .. . ) 
• /src/main/webapp : project web application 
• / src / test : test files 
• /src/test/java : test source code 
• /src/test/resources : files and resources for the tests 
• /src/site : information about the project and/or the generated reports 
bound to realized treatments 
• / target : result files, binaries ( code and tests). generated packages et 
results of the tests 
Based on the structure of these repositories, Maven introduces principal com-
mands to build the software product : compile, test, package, install and 
deploy. For example, mvn package will compile all the Java files. run all the 
tests, and package the deliverable code and resources into the repository target 
under the file my-app-1. O.jar (if the pom.xml file respects the coordinates of 
the example given before). In terms of the objective needed and the command 
called, all other commands upstream must be executed ( excepted when they 
already have been executed with success without any change since the last 
command) . For example, for mvn install, Maven will verify that mvn package 























Here is the structure of the different phases introduced by Maven to build 
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Figure 3 .1: The clifferent options offered by Maven to builcl an artefact from 
code source 
So, each phase is associated with one or more goals of different plugins such 
as install.jar given by Maven. 
In general , users don 't have to write plugins themselves to configure 
the project because Maven alreacly offers some to do the commonly aokecl 
work : compile the project, clean target directories, run unit tests, generate 
API documentation, ... 
Practical reasons led to the development of Maven and its use in 
enterprises : 
• No standard structure for projects 
• No metadata available about the projects 
• Classpaths to rebuild on each work station 
• No verification of dependant jar versions 























• Tedious versioning 
• Important risks due to possible edge effects when compiling software 
products on other machines 
Maven and its development brought advantages for the enterprise developing 
Java EE software products; here are some examples : 
• Standardized structure for the projects based on conventions 
• Ceutralized pom.xml file to parametrize the projects 
• Automatic management of dependencies 
• Possibility to centralize dependencies and generated projects 
• Structured management of versions 
• Constant results after compilation 
• Continuous integration easy to implement 
• Available and useful plugins for Maven : javadoc, website, unit tests, ... 
However, Maven bringn different drawback8 : 
• Project structure to respect : the users need knowledges and exper-
tine to une Maveu effi.cie11tly 
• Structure for software products releases to respect : Different 
rules must be respected to create the releases of the software products 
• Non adequacy of the basic structure of the projects: Sometimes, 
projects requirements imply some structure, far different from the basic 
imposed by Maven 
• Compiling time longer : More sources to compile, more dependencies 
to check, ... 
The disadvantages are much less restrictive than benefits that Maven bring. 
Furthermore, the quality of the deployed software products and the insurance 






















Spring is a platform independent and open source application framework 
model to buikl and configure the infrastructure of a J ava application which 
benefits from different feat ures introduced by the framework. Spring was first 
released under the Apache license in June 2003 and the current version is the 
4.0 which was offered in December 2013. 
The framework introduces different modules which provide a set of 
services, here are different examples : inversion of control , Aspect-oriented 
programming, data access with object-relational mapping tools and with 
NoSQL dat abases, transaction management , . .. 
Inversion of control ( dependences inject ion) it consists in a 
container which provides a means to create, configure and manage Java 
abjects. The container manages objects lifecycle : creating these obj ects, 
calling their initialization methods and configuring them by bounding them 
together. 
The container which contains the beans ( or abjects created by the 
container) loads XML files or detects specific annotations in Java code to 
configure the beaus. These files or annotations permits to defiue t he bea11s 
and contains the information to create them. 
There are two ways to retrieve the abj ects : dependency lookup and 
dependency injection. Dependency lookup pattern permits to ask the con-
tainer for an object with a specific name or of a specific type while clepenclency 
injection pattern consists in the passing of t he objects by t he container by 
name to other objects via constructors , propert ies or factory methods. 
The use of the container is not mandatory but makes an application 
easier to configure and customize. The benefit of using Spring container is 
that it offers a mechanism to configure applications and that it is integrable 
with almost all Java environments for all applicat ions, as well the smallest 
ones as the largest in enterprises. 
It is possible for the container to be compliant with an EJB 3.0 container. 
However , Spring is not often compliant with other st andards as its develop-
ment didn't have as objective to be adaptable with other standards as its 























consist directly in the creation of an object but describes how they should be 
created by defming it in the Spring configuration file or with the annotations in 
the Java code. It is the same for the services and the components. This vision 
makes the code easy to maintain and easier to test through inversion of control. 
Inversion of control introduces benefits for the development of appli-
cations such as transparent objects factories , dependencies between objects 
injection, decoupling between the Java classes, optimization of loading time, 
and so on. 
Aspect oriented programming (AOP) : Spring framework possesses 
its own AOP framework which modularizes inter-classes concerns in aspects. 
The motivation to create an AOP framework in Spring is to provide basic 
AOP features in design, implementation or configuration tasks which take full 
advantage of the Spring container. 
The Spring AOP framework , configured at run-time, is based on the 
µroxy pattern. The be11efit is that it removes the loss of tirne due to the 
compilation step and to the load-time. However , it implies that only public 
method execution on existing objects can be caught in join points. It is 
recommended to complete the application with other frameworks like AspectJ 
to create aspects which do not consist only in the execution of methods at 
run-time. Spring AOP offers an excellent base and solution to most problems 
in Java EE applications concerning the AOP. 
Spring AOP is less powerful but less complicated compared to As-
pectJ. The container of Spriug permits to configure <lirectly the aspects. 
However, the framework keeps functionalities from AspectJ. For example, the 
language used to declare pointent can be reused and mixed with aspects of 
Spring AOP. 
Spring provides two approaches for the configuration of the AOP in 
Spring : the approach based on the schema definition in a configuration file 
and the AspectJ annotation style directly in the Java code. 
Data access : In applications working with database, it is corn-
mon to meet difficulties during the development. Spring offers a data access 























supports were provided with the birth of Spring for the popular data access 
frameworks working with the Java language : JDBC, Hibernate, JPA, Oracle 
TopLink, Apache OJB, Apache Cayenne, ... 
Spring provides features to support the popular frameworks such as re-
source management to automatically gain and release database resources, 
exception manipulation to translate the exceptions related to data access to a 
Spring data access hierarchy, transaction participation which is a transparent 
participation in ongoing transactions, resource unwrapping which consists 
in t he recovering of database abjects from connection pool wrappers and 
abstraction to process Binary Large Object (BLOB) and Character Large 
Object (CLOB) which are commonly used in databases. 
Developers benefit from these features when they use Spring's tem-
plate classes relative to the framework. However, some say that these 
template classes are intrusive and do not offer any advantage in using 
one feature directly. To respond to the limitations of the features, Spring 
introduced combinations of features such as the use of Hibernate and JPA 
APis directly together. Sorne of these combinations required the support 
of others features like the transparent transaction management to help the 
developers to withdraw their responsibility in the obtaining and closing of 
database resources and in exception translation. 
Furthermore, transaction management feature, in combination with 
the previously cited: permit to Spring data access framework to offer a 
flexible ab8traction to work with data acceirn frameworks. It i8 important to 
notice the Spring framework is not a common data access API and it keeps 
intact the power of the supported APis. The management of data access 
environments is possible for Java, thanks to Spring, the only framework whose 
these environments are outside of an application server or a container. 
Other modules exist through which Spring offers services and the 
framework continues to evolve through the new releases. It is doomed to be-
corne a standard to build and configure the infrastructure of Java applications 
and to evolve through rich functionalities and documentation for the users 
through releases of new versions of the framework, as well for particular use 
as for enterprise projects. Differeut features anrl. characteristics of Spriug will 
permit its sustainability. Furthermore, Spring is widely used in the Java world 






















sm,tainability. Spring brings benefits. Indee<l, it offers a powerful integration 
of external open-source frameworks and Java standards and its use is possible 
as well on Java EE servers as with a simple web container or a standalone 
application. However , Spring includes different disadvantages such as its 
establishment at the begi1111i11g of projects. There exist.s rl.iffereut. solutions to 
implement a functionality, for example, the use of this functionality through 
XML configuration, annotations or an API. According to the needs, the choice 
for such and such implementation requires a certain arbitration even if Spring 
offers different choices. Furthermore, Spring implies heavier deliverables due 
to the dependencies with libraries required by the framework. 
Such disadvautages are uot rest rictive cmnpared to the benefits the 
framework offers. Spring continues to evolve to become a standard , introduc-
ing a large range of functionalities and documentation, applicable on different 
environments and easily usable on small proj ects as in enterprise. 
1.3 Hibernate 
Hibernate is an object-relational mapping library for the Java language 
which provides a framework to map an object-based domain model to a 
relational database. The framework permits to resolve a set of conceptual and 
technical difficulties that are often encountered when a relational database 
management system is used by a program written in an object-oriented 
programming language (i. e., when abjects or classes definitions are mapped 
to database tables or relatioual schema). Hibemate solves these difficulties 
in replacing direct persistence-bound database accesses with high-level object 
manipulation methods. Hibernate is free and available under GNU Licence. 
The motivation to introduce such a framework was to offer a solu-
tion to the problem called "object-relational impedance mismatch". In the 
majority of applications, the abjects in the front-end application are based 
on object-oriented programming principles while the abjects in the back-end 
are bound to database normalization principles. Such an application results 
in different possibilities to represent requirements. This is what is called 
"object-relational impedance mismatch". 
To solve this problem, Hibernate offers different primary features 
such as the mapping between Java classes and database tables and from Java 
data types to SQL data types. It also iutroduces differeut kiud of queries 























framework automatically generates SQL calls and helps the developer in the 
manipulation of the result sets returned in response of the queries and in the 
conversion of entity types ( or tables) and data base types in the corresponding 
types in the Java language. The use of Hibernate implies little overhead of 
performance when it is used in applications to support the manipulation of 
data in SQL databases. 
There exist two ways to realize the mapping between Java classes 
and database tables, similar to Spring : the configuration of an XML file or 
the use of Java annotations. Thus, Spring and Hibernate are in the same 
way easily configurable and often working in pair. Hibernate is able to 
geuerate a cocte source skeletou from the XML configuration file for the classes 
used for persistence. Here is an example using a XML file for the mapping 
configuration : 
First, the Java class code representing the Employee object : 
1 public class Employee { 
2 pri vate int id; 
3 private String firstName; 


























public Employee() {} 
public Employee(String fname, String lname) { 
this.firstName = fname; 
this.lastName = lname; 
} 
public int getid() { 
return id; 
} 
public void setid( int id) { 
this.id = id; 
} 
public String getFirstName() { 
return firstName; 
} 
public void setFirstName( String first_name) { 
this . firstName = first_name; 
} 
public String getLastName() { 
return lastName; 
} 
public void setLastName( String last_name) { 
this.lastName = last_name; 
} 




















1 create table EMPLOYEE ( 
2 id INT NOT NULL auto_increment, 
3 first_name VARCHAR(2O) default NULL, 
4 last_name VARCHAR(2O) default NULL, 
5 salary INT default NULL, 
6 PRIMARY KEY ( id) 
7 ) ; 
And finally, the XML configuration file to define the mapping between the 
database table and the Java abject : 
1 <?xml version="l.O" encoding="utf-8"?> 
2 <!DOCTYPE hibernate-mapping PUBLIC 
3 "-//Hibernate/Hibernate Mapping DTD//EN" 
4 "http://www.hibernate . org/dtd/hibernate-mapping-3.0.dtd"> 
5 
6 <hibernate-mapping> 
7 <class name="Employee" table="EMPLOYEE"> 
s <id name="id" type="int" column="id"> 
g <generator class="native"/> 
10 </id> 
11 <property name="firstName" column="first _name" type="string"/> 
12 <property name="lastName" column="last_name" type="string" /> 
13 <property name="salary" column="salary" type="int"/> 
14 </class> 
15 </hibernate-mapping> 
Such a XML configuration file is smaller when annotations are used to realize 
the mapping. Indeed, the configuration file will only consists in the definition 
of the différent classes where aimotat.iom, are used. Here is au example of the 
use of Hibernate annotations. 
First, the SQL code representing the Employee abject 
1 create table EMPLOYEE ( 
2 id INT NOT NULL auto_increment, 
3 first_name VARCHAR(2O) default NULL, 
4 last_name VARCHAR(2O) default NULL, 
5 PRIMARY KEY ( id) 
6 ) ; 
Then, the corresponding Java class code to represent the Employee abject, 
using annotations to define the mapping with the database : 
1 import javax.persistence.*; 
2 
3 ©Entity 
4 ©Table(name = "EMPLOYEE") 
5 public class Employee { 
6 ©Id ©GeneratedValue 
7 ©Column(name = "id") 
s private int id; 
9 
















































private String firstName; 
©Column(name = "last_name") 
private String lastName; 
public Employee() {} 
public int getld() { 
return id; 
} 
public void setld( int id) { 
this.id = id; 
} 
public String getFirstName() { 
return firstName; 
} 
public void setFirstName( String first_name) { 
this.firstName = first_name; 
} 
public String getLastName() { 
return lastName; 
} 
public void setLastName( String last_name) { 
this.lastName = last_name; 
} 
The annotations offer a way to define automatically the mapping between the 
database tables aud the Java abjects. Here, au eutity is defiued with the 
@Entity annotation. Then, the Java attributes are mapped with the database 
columns, plus the identifier through the corresponding annotation, bound with 
an option to increment automatically the value of the identifier in the database 
when a new entity is created. 
Finally, the XML configuration file to clefine the different classes using anno-
tations, permitting to use the abjects in the production code : 
1 <?xml version="l.0" encoding="utf-8"?> 
2 <!DOCTYPE hibernate-configuration PUBLIC 
3 11 -//Hibernate/Hibernate Configuration DTD 3 . 0//EN" 
4 "http://www.hibernate.sourceforge.net/hibernate-configuration-3.0 .dtd"> 
5 
G <hibernate-configuration> 
7 <mapping class = "Employee" /> 
8 </hibernate-configuration> 
Both techniques presented here permit to use the Employee abject directly in 
the production code with simple Java operations which directly make the link 
with the real abject contained in the database , thanks to Hibernate. 
To complete the features offered by the technology, Hibernate allow 
the developers to write personalized queries for database data, through a 























permits to write queries which look like SQL ones, directly on Hibernate's 
data abjects and their properties. The objective of such a language is to offer 
a common language for all types of databases to query the data. The interest 
of HQL is to be independent of the underlying database : the SQL request 
will he generate<l by Hibnuate frorn HQL iu terms of the specifie<l <latabase. 
Therefore, the HQL language is close to SQL. No reference to tables 
or fields are used to request the data, they are respectively referenced by the 
corresponding classes and properties. Hibernate is in charge of generating 
the SQL requests from HQL requests taking into account the context (types 
of the data used which are defined in the configuration file and in the 
mappiug configuration). HQL and SQL syntaxes are similar ; the major 
difference is that HQL uses abjects and their properties while SQL uses 
tables and their columns. It is important to notice that HQL requests are 
case-insensitive; it is not the case for the the names of the classes and variables. 
The benefits of Hibernate is that it can be used both in standalone 
Java applications and in Java EE applications. For other programming 
languages, it is possible to add Hibernate as a feature. As previously said, 
the framework offers its own native API, and is also an implementation of 
t.he Java Persisteuce API (JPA) specificatiou. Therefore, Hibernate is usahle 
in any environment which supports JPA. For example, it can be used in Java 
SE applications, J ava EE application servers , ... Furthermore, Hibernate 
permits to implement persistent classes for data abjects maintaining the 
benefits of object-oriented languages such as inheritance, polymorphism, 
association, ... Moreover, any class and data structures can be persistent with 
Hibernate which permits to avoid the use of interfaces or base classes for the 
persistent classes. Hibernate also promotes high performance through support 
in lazy initialization, numerous fetching strategies and optimistic locking 
with automatic versioning and time stamping. The framework also gains 
some time in the generation of the SQL requests at the system initialization 
instead of at runtime. Hibernate provides better performance as well for 
developer productivity as for runtime performance. Hibernate is also known 
to be reliable through its stability and quality and extensible as it is highly 
coufiguraole. 
1.4 JavaFX 
.JavaFX is a software platforrn offered l>y Oracle. The objective of the JavaFX 























run on a large family of devices. JavaFX already introduces products and 
technologies and is still evolving through new releases. The advantage of 
using such a technology is that it uses a SDK which is integrated directly in 
the standard Java SE JDK. Therefore, no specific installation for JavaFX is 
needed. The platform is seen as the successor of Swing to be the standard 
GUI library for Java SE. However, Swing and JavaFX will both continue 
to be used in the future as they are widely used in the Java world. The 
platform is compatible with different environments, as well for local as for 
web applications. 
The first version of JavaFX only permitted to developers to use a 
statically typed and declarative language to create applications; the lan-
guage was called JavaFX Script. This language offered a compiler which 
produced Java bytecode from JavaFX Script code. Therefore, developers 
began to include this language directly in their Java code to compile both 
together to get Java bytecode. JavaFX was at first introduced to create 
applications which could run on any computer working with Java SE, on any 
browser working with Java EE, or on any mobile phone working with Java ME. 
Latest versions offer JavaFX as a native Java library. Therefore, the appli-
cations working with JavaFX are developed in native Java code. Concerning 
JavaFX Script , the development continues through different projects but Ora-
cle has abandoned the language evolution. Unlike the first version of J avaFX, 
the version 2 in incompatible with mobile phones applications, and different 
environments are no longer appropriate to use the technology such as Solaris 
operating system. However, with the latest version 8 of JavaFX, different 
frameworks are being tested to cover the mobile applications and Oracle 
tries to integrate more environments in the new releases of the technology. 
Concerning the applications on computers, latest versions of JavaFX support 
the primary environments, i.e. Windows XP and newer, Mac OS X and Linux. 
Nowadays, more and more mobile applications are developed to fol-
low the evolution of the mobile phones and other devices. Therefore, Oracle 
introduced JavaFX Mobile which was the implementation of JavaFX for rich 
Internet applications for mobile devices. JavaFX Script was used to develop 
such mobile applications and tools offered by the first versions of JavaFX 
were compatible with mobile application development such as the JavaFX 
SDK. The benefit to reuse the older tools and JavaFX Script language is that 























shared among local and mobile applications. Furthermore, JavaFX applica-
tions for mobiles can benefit from Java ME to have access to the features of 
the devices, such as the camera, the GPS , the bluetooth, ... JavaFX Mobile is 
now compatible with multiple mobile environments, as well the most known 
like Android and Windows Mobile as proprietary operating systems. 
Therefore, the introduction of JavaFX brings two primary benefits 
to the development of GUI applications, but also to Java developers. Indeed, 
the technology permits to integrate different uncommon options for the 
interfaces such as vector graphies, animations, sounds and videos recovered 
on the Internet in a rich, dense and interactive application. J avaFX also 
extends Java technology through the possibility to include any Java library 
directly in the JavaFX applications. Unlike most of GUI languages, JavaFX 
introduces two ways to develop applications : the commonly used method 
which consists in coding the application and the graphies directly in the same 
code like Swing, or separate the visual components code from the application 
and controller code. The last method is pm;sible, thanks to JavaFX fxml files. 
Such files are based on XML to describe the interfaces components and their 






















Here is an example of a JavaFX application in which code bound to the 
interface is separated in XML files from the application code and the controller 
bound to the controls of the interface. The fxrnl file con tains t lie informa-
tion of the interfaces components, their identifier and their potentials listeners : 
Here is first the definition of the components describing the final inter-
face: 
1 <?xml version="1.0" encoding="UTF-8"?> 
2 
3 <!-- Definition of the main pane (a grid pane to place the different 
components in a tabular form --> 
4 <GridPane id="root-pane" fx:controller="fxmlexample.FXMLController" 
5 xmlns: fx="http : //javafx . com/fxml" alignment="center" hgap="10" 
vgap="10" styleClass="root"> 
6 <! -- A controller is defined to bind the interface components and 
listeners with the Java code--> 
1 <! -- Other options are introduced to configure the grid pane such as the 
spacing between the different elements of the table--> 
8 
9 <Text id="welcome-text" text="Hello" 





<Label text="User Name:" 


























<Button. text="Sign In" onAction= "#handleSubmitButtonAction" 
GridPane . columnlndex="1" GridPane.rowlndex="4"/> 
<! -- This textual component can be retrieved in the controller class 
through a parameter defined as "actiontarget" --> 
<Text fx:id="actiontarget" 
GridPane.columnlndex="1" GridPane .rowlndex="6"/> 
<!-- Style sheets permit to use CSS options to personalize the 
interface components (colors, size, effects, ... ) --> 
<stylesheets> 
<URL value="©Login.css" /> 
<./ stylesheets> 
35 </GridPane> 
It is possible to define every interface components, their characteristics and 
their listeners through fxml files. It is important to notice that every fxml file 























the lü,tenen, introduced in the fxml file. It is also possible to personalize the 
interfaces using Cascading Style Sheets (CSS). Here is now the corresponding 
controller to manage the listeners bound to the components describes in the 
fxml file : 
1 import javafx.event.ActionEvent; 
2 import javafx.fxml.FXML; 
3 import javafx.scene . text .Text; 
4 









©FXML private Text actiontarget; 
©FXML protected void handleSubmitButtonAction(ActionEvent event) { 
actiontarget.setText("You pressed the button"); 
} 
With annotations, it is possible to retrieve the interface components described 
in the fxml file directly in the Java code to realize the operations bound to 
the component under focus by the user. This simple example permits to un-
derstand how interfaces components are retrieved in the controller to realize 
operations on them. Here is now the Java main class to establish the final 
application with the two classes defiued hefore : 
1 import javafx.application.Application; 
2 import javafx .fxml.FXMLLoader; 
3 import javafx.scene.Parent; 
4 import javafx.scene.Scene; 
5 import javafx.stage.Stage; 
6 






















public void start(Stage stage) throws Exception { 
} 
Parent root = FXMLLoader.load(getClass().getResource("FXMLExample 
.fxml")); 
//Definition of the interface size 
Scene scene = new Scene(root, 350, 325); 
//The Scene is the content of the interface 
stage.setTitle("FXML Welcome"); 
stage.setScene(scene); 
//The Stage is the interface created 
stage. show(); 
//The interface is showed to the user 
//The main method simply calls indirectly the "start" function 

























2 Technical infrastructure 
In this section, the technical infrastructure will be presented. Firstly, the 
interna! infrastructure will be introduced to explain how the local and remote 
servers are connected with the developers of the Java team and how to use the 
structure efficieutly. Theu, the application servers structure will be preseute<l 
to show how the OmniPro modules are created and how they work when they 
are deployed on application servers. Furthermore, the structure will show how 
the users of the applications canuse the modules offered by the Java cell. 
2.1 Internai Infrastructure 
The technical infrastructure in the Java cell consists in three main servers 
which are interconnected via users between them. One user works on his 
persona! IDE and his own Maven repository. 
When the developer needs a new library for its project through a 
dependency he added in the pom file , Maven first checks if the library in 
question is available directly in the local Maven repository of the user. In the 
positive case, the library is added to the project of the user via an automatic 
dependency injection. If not , Maven will search after the library on the Nexus 
server which is a central Maven repository which contains the commonly 
used dependencies in the cell. It is possible that the server doesn't contain 
the needed library. In that case, the server directly check on the Internet on 
public repositories to find the artefact. The server adds it to its repository 
aud to the local repository of the user which eau heuefit from the <lepemleucy 























Here is the representation of the process to obtain the needed dependencies 
for the developers projects : 
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Figure 3.2: The different Maven repositories of libraries and the activities 
between the different parts 
To share the projects and the code, the developers store their work on a 
centralized SV server. The server contains all the versions of the modules 
implemented but also other sources files such as SQL scrip ts, pom XML files to 
huil<l the Maveu projects aud other sources use<l iu the projects (fxml files for 
JavaFX interfaces definitions, images, beans, ... ). The SVN server is main-
tained in the Jenkins tool which realize a continuous integration of the sources 
contained in the SVN. According to modified files, J enkins compiles all the 
sources of the proj ects after having resolved the dependencies bound to the 
projects. Therefore, the tool is bound to the Nexus server which contains all 
the necessary libraries for the compilation with the sources. Finally, J enk-
ius geut>ratt>s autornatically the rt>least>s of tlw projects (suapshots aml. final 






















Here is the representation of the process to commit the sources on the SVN 
and the continuous integration with Jenkins : 
1. File edition in the IDE = Nexus 
œi] Enterprise repository 
4. Dependencies resolution Oar libraries) 
IDE 
Q J enkins : continuous integration 
J ~SUBVERSION m aven 
Modified source files Version Control Build Manager 
2. SVN commit 
3. Modification detection 
6. Periodical compilation of source 
code from SVN 
7. Automatic generalion of the 
releases Oar, website, ... ) 
Figure 3.3: SVN, Nexus and Jenkins servers and their relations in the process 
to build a software product 
This internai infrastructure is very interesting for the development of J ava EE 
applications. Indeed, it permits to avoid many difficulties uch as versioning 
when several developers work on the same project and dependencies problems 
which happen when developers use different versions of external libraries. The 
infrastructure also help the developers not to confound releases states because 
Jenkins binds a suffix to know the state of the application integrated (snapshot 
or release version) and adds a versioning number in the release built by the 
process. Furthermore, the SVN server provides a way to gather all the sources 
from the developers in distinct repositories according to the definition of the 
project defined in the pom.xml and these sources are available for all the 
team members. The continuous integration permits to check periodically if 
the integration of sources files with the dependencies is working and creates 
snapshots or releases of the modified projects which offer a way to test and 























2.2 Application servers structure 
The development of J ava modules in the enterprise consists in the use of a 
layered structure which represent all the aspects of a typical program from 
the database to the concrete view for the final users of the application. The 
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Figure 3.4: Application servers layered structure 
Such a structure offers a powerful mean to separate the most important points 
of interest in different sub-modules. Therefore , a general module developed 
in Mims Java cell is typically composed of 5 layers . From the lowest layer to 
the uppermost one, we have the Data Access Objects (DAO) , the Business 
Objects (BO), the Business Facade (BF) and the view layers. In addition to 
these layers , the JPA entities layer is bound to each one to offer them a way 
to manage the Java objects which represent the entities from t he database 
and their relationships. Such a way to separate the sub-modules permits 
to reduce coupling and improve the reuse of fonct ions. Furthermore, it of-
fers a middle to store the code in the appropriate category depending on its use. 
The DAO layer provides a way to manage all the requests ( queries 
and responses) concerning the database and its content. Uppermost layers 
call t he operatious offered by the DAO t hrough an interface bouud to the 
lowest layer. The objects contained in the layer are based on Hibernate 























The BO layer offers a range of business fonctions for the verification 
of the database requests and their parameters, the operations to real-
ize commonly used calculations, the verification of regular expressions, 
... Therefore, this layer concerns the business aspect of the application, 
which do not include DAO, interface or JPA entities operations. This 
layer is used as the transition between the DAO layer (via the use of the 
interface offered) and the BF through an interface it offers to uppermost layers. 
The BF layer is a translation layer able to respond to diUerent re-
quests , sort out and translate them in the correct format to be used in the 
lowest layers. It is in fact a transparency layer between the external requests 
in different languages and syntaxes, and the underlying real operations 
which are implied according to the objective of the request. For example, it 
translates a request concerning the medical axis to the correct object which is 
in charge of the management of medical axis operations in lowest layers. The 
BF uses the BO interface to call the correct operations bound to the requests 
received and offers an interface for the client view or for an application server. 
The View is the transition layer between the final user and the module 
and its operations through an user interface. There exists two ways for its use 
: either the user is directly connected to the web service interface through 
the interaction between him and the interface offered by the service, or the 
requests of the user pass through another application server which is in fact 
an intermediate web application which is connected to the central application 
server and which transposes the user requests to the BF interface through 
XML, Jason or other web format languages. The second use is most commonly 
employed as the central server is not always directly achievable from the 
external users. Furthermore, the first use is preferred by the developers 
for their tests and at the beginning of the development to realize the basic 
operations and interfaces of the modules before moving to the second solution 
to prepare the application for the future use and to test the management of 
distant user requests. 
The JPA entities layer contains the created beans (or objects) es-
tablished by the developers and which are bound to the entities of the 
database. Operations concerning the management of the database are done 
through these objects which are introduced according to the object-relational 























attributes and fonctions ( constructors, getters and setters and other fonctions) 
and are bound to the database according to the method used : definitions 
of the mappiug iu the configuration file or with aimotatiom; clirectly iu the 
Java classes. The layer is available from every other layers to allow their 
management in all the contexts of use in the development of the module. Such 
beans are also used by the DAO layer to realize the operations on the data of 
the database : selection, insertions, updating, removing, ... These activities 
are directly transformed in SQL queries to query the database, thanks to 
Hiberna te. 
The database with contains the helpful data is directly connected to 
the sub-module which represents the DAO layer. It permits to realize the 
mapping between the data and the Java beans and to achieve the operations 
on the data directly from the Java code in the DAO. 
Concerning the development of modules according to the structure 
presented above, the enterprise offers an archetype to directly create a new 
Java project (module) with the correct sub-modules which represent the 
differeut layers. The archetype also µennits to configure the eutire project 
through Maven pom.xml files in each sub-modules and to inject the depen-
dencies, concerning the links between the sub-modules and the technologies 
used, directly in these files to have a complete and functional project with its 
sub-modules and configuration files filled. Therefore, the developers work on 
the same architecture for every projects, making them easily understandable, 
reusable and without creation or project configuration errors. The developers 
just need to use the archetype adapted for Maven installation to create a new 
project (module) and to start the development of their project. 
3 Database 
OmniPro has been created to offer a computerized support to the management 
of patients records in hospitals. For this purpose, the enterprise introduces 
a complete suite of 21 modules which cover three main axes in hospitals : 
the medical, the nurse and the organisational axes. Each module has been 
developed as a complete product and not as a sub-module of OmniPro. 
Tlwrefore, each mo<lule eau operate autcmomously. For example, Mirns offers 
OP'Order for computerized prescription examinations and OP'Drug for drugs 
management and monitoring; these modules can work without laboratory or 























autonomous modules imply significant developments and work, but also a 
large range of database structures to help the modules in the storage and the 
creation of data. Therefore, Mims established a centralized Oracle database 
but also locally to hospital databases to support the efficiency of the modules 
offered to the clients. 
In that way, Mims main database counts nowadays more than 850 
tables with millions of data records. The amount of data continues to increase 
and different tables already contain up to millions of lines in first hospital 
customers databases. For example, the table Objets deployed at the end of 
1990 in the CHC database counts about 20 millions of records. Furthermore, 
early versions of the database contain special structures to represent several 
information in a single cell in the database using a multi key-value structure. 
Therefore, it is possible to represent many information in one single cell which 
consists in a large text area with identifiers marked with tags and multiple 
possible sorted values with separators. Such a structure is still used in the 
development and in the use of OmniPro modules developed in the Visual 
Basic language. However , the same database is used in the Java cell to realize 
and update the new modules; it implies to improve and complete the database 
with new structures, tables and columns , foreign keys, . .. The database now 
possess an extremely large structure of data, with sometimes redundant, 
useless and no longer used information, making the storage, the manipulation 
and the work on data heavy. 
To fill this gap and to adapt the evolution of the database with the 
development of modules , the company can rely on Oracle benefits, efficient for 
large data storage. Furthermore, Oracle databases are known to be secured 
for the manipulation of coufideutial data, which is the case with medical 
and patient information in OmniPro modules, and available as well locally 
as remotely, permitting to users to have continuous access to the authorized 
patients information. Oracle databases are also the most used in the world 
and possess a wide range of documentation : tutorials, compatible programs, 
add-ons, official documentation, forums, ... Above all, Oracle is used for 























Administrative management of 
clinical studies 
1 Methodology 
As previously said, my internship took place in Mims enterprise, specialized 
in the computerization of patients records in hospitals. My participation 
in the project consisted in the creation of a new module, OP'Study, which 
brings support to the management of clinical studies. This module had 
to be compatible with the technical infrastructure of Java projects in the 
enterprise, both in terms of technologies and interna! infrastructure as for the 
database structure, allowing the reuse and the continuation of the module 
in Mims enterprise and at the UNamur at the end of the internship. Like 
any module offered by the company, OP 'Study had to operate autonomously, 
and developed as a complete product and not as a sub-module of OmniPro. 
Therefore, it was possible to expand and test the new module independently 
of the others, while remaining it linked to the advocated infrastructure in 
the Java cell and to data structures used by other modules. The requested 
module consists in 2 main components : the administrative management of 
clinical studies and the scientific aualysis; the first bei11g my objective for rn.v 
internship during 5 months. The entire module was estimated to be released 
after 2 years of development. 
The development of my part of the module consisted in 4 main activities to 
complete the project and achieve the expected results. Firstly, it was essential 
to read, document and control the technical infrastructure established in the 
Java cell , the technologies used and the database structure of the enterprise. 























studies and understand all the bound concepts, plus set a targeted perimeter 
for my contribution in the project. Then, the project infrastructure has 
been implemented , as well for the completion of the database structure and 
the establishment of the infrastructure of the project as for the creation of 
iuterfaces ri.rafts to present a poteutial fiual users view for the arl.miuistrative 
management of clinical studies to the interested persons in the hospital of 
Mont-Godinne. Finally, the module development started up to the end 
of the internship to obtain the final expected deliverables. Meanwhile, 
meetings with end users and people associated with the project in Mims 
enterprise and UN amur were held to share the progress of the development 
and to share the adaptations to bring according to requirements and new goals. 
So, the first objective was to learn MIMS Java development cell technical 
infrastructure for the establishment of projects, understand the structure 
of the database and read documentation, follow presentations and realize 
t utorials about the technologies used in the cell. I worked on these points for 
about a month. 
For the next few weeks it was essential to gather information and to 
understand the concepts concerning clinical studies. The initial request 
for the creation of the module came from a professor in the hospital of 
Mont-Godinne, with the support of Mims enterprise and the UNamur for the 
development and the establishment of such a project. To start the project , 
it was indispensable to identify the future users requirements of the hospital. 
Last year , a student in computer science had a baccalaureate project on 
clinical studies. His objective was to meet employees in UCL Mont-Godinne 
to target their requirements about the computerization of clinical studies. 
Not to further disturb the future users , we decided to reuse the realized 
analyses and interviews to have a better comprehension concerning the needs 
of the final users. Furtherrnore, to stay in touch with the users of the future 
module, a meeting has been fixed with Benoit Martin, the data manager 
for haematology in the hospital of Mont-Godinne. Regularly during the 
internship, meetings were set to discuss about the results and the adaptations 
to provide to the application. 
Once the knowledge gathered and the subject controlled, my task consisted 
then in the realization of a conceptual schema for the new entity types and 
association types linked with data structures in MIMS database. Indeed, 






















records to link them with the new constructions needed for the computeriza-
tion of clinical studies. After corrections, the SQL code was produced from 
the schema and the new constructions and constraints were added to MIMS 
data base. 
Before the beginning of the development of the module, it was important 
to realize a first draft of the interfaces for the future application. To ensure 
the expected results, discussions with Benoit Martin took place to talk about 
the view of the application and after modifications , every information was 
gathered and confirmecl to start the development. 
The first task iu the developmeut cousiste<l i11 the use of Hihernate with 
JPA to create the beans and the mapping with the necessary entities in the 
database. Once the ob_jects created, the sub-modules to manage the different 
layers of the technical infrastructure were established with the help of the 
archetype provided by the Java cell. To complete the application, the next 
task consisted in the development of the the interaction between the interfaces 
and the database. Modelling and development phases last for around 7 weeks. 
During these weeks, regular meetings with the data manager of haematology 
were fixed every 2 weeks to present the progress of the project and provide 
the appropriate rno<lificatious to the application. 
At the end of the development , a meeting has been fixed with my professor 
to plan the continuation of the internship. It resulted in the idea to find a 
research question concerning clinical studies. Therefore, the focus has been 
placed in the reporting of the results of patients examinations included in 
clinical studies. Indeed, there is no automatic standard used by sponsors of the 
clinical studies to recover such data. The scope of the research was limited to 
the CDISC organisation which provides standards for the researches in clinical 
studies related with healthcare, and in particular in the reporting of clinical 
results. The researches on the subject took place during the last weeks of the 
internship, up to the end of January. 
2 Infrastructure 
In this section, the rl.iffereut parts of the rl.evelopmeut of the module will he 
presented, concerning the administrative management of clinical studies. In a 
first t ime, an explanation will be introduced to present the differences between 






















and the infrastructure established for the component of the module concerning 
the internship . Then, a presentation will be given about the creation of the new 
entities types and their relationships between them and the existing ones in the 
main database of the enterprise. Furthermore, a logical schema will be offered 
to understand the concepts and the objects needed for the development of such 
a sub-module. Finally, the development of the component will be explained to 
present the process of building such an application in an enterprise. 
2.1 Technical infrastructure 
As previously explained, different infrastructures are introduced in the enter-
prise to be reused for an optimal development of modules. Such infrastructures 
concern the internal infrastructure with the servers deployed to manage Maven 
dependencies with local repositories, SVN activities and Jenkins continued 
integration. Mims Java cell also provides a generic infrastructure for the 
development in layers of the modules deployed as web services for the clients. 
The internal infrastructure has been reused directly in the development 
of OP'Study to facilitate the creation, to share the sources and the project, 
and to realize continuous integration to obtain a mean to test the application 
during the development. 
Concerning the module infrastructure and its deployment as a web service, 
different reasons implied a different way to realize the module. Indeed, the 
internship available time was too short to realize all the basic functionalities 
and offer them as web services. Furthermore, the web technologies used for 
such applications are time consuming in the development and implied to 
learn them, plus the fact that these technologies were not yet taught in our 
cursus at the univer ity. Therefore, a different project infrastructure has 
been m;ecl to imµlement the comµonent of the module. The final user uses 
normally a web service to send his requests to the Business Facade interface 
with or without an intermediate application server between him and the 
main application server. To facilitate the development and avoid the use 
of web technologies in the development of the module component, the web 
service layer was omitted to use a local infrastructure which consisted in the 
development of a client view directly connected to the interface of the BF 
layer, without passing through a web service. However, the archetype offered 
for the creation of new Java modules has been used to establish OP'Study, 
offeriug the differeut µreseuted layers, i11cludi11g the web services 011e. The 






















two different implementatiorn,, one which conëü,ts in the uëe of a web ëervice 
to respond to remote users requests , and the local one which bind the client 
directly with the BF interface which works locally with the underlying layers. 
Such a structure implied to use the new module locally, directly connected 
to the main database. Therefore, it was impossible to test the application out-
side the local network of the cell. Sometimes, different meetings were organized 
in the UNamur and at the hospital of Mont-Godinne, making the teleworking 
and the presentation of the module impossible. To satisfy this gap, a VPN 
connection has been established to connect directly to the local network of 
the Java cell in the enterprise, permitting to work remotely on the module. 
Such constraints will be resolved, using web services in the next versions of the 
OP'Study module, under the management of the Java cell members which pick 
up the project for the rest of the development and for the second component 
concerning the scientific analyses of clinical studies. 
2. 2 Database 
Concerning the adaptation of the database and the creation of new entity 
types and relationships, different activities were realized to respond to the 
requirements for the creation of the module in charge of the administrative 
management of clinical studies. The new module had to work autonomously 
and independently of other modules. However, these modules are inter-
connected via the database they use for their operations, and sometimes 
via ciepeucieucies betweeu thern wheu they are combiued for different purposes. 
Therefore, the development of OP'Study required new entity types and re-
lationships to respond to the clients requirements, and to work autonomously. 
However, it also involved the reuse of existing database structures convenient 
for the objectives of the application. Therefore, Mims database specialists 
fixed meetings to explain the global structure of the database and the 
rnaiu useful eutities. After aualysis , it was fouu<l that <liffereut tables were 
interesting for clinical studies data purposes such as structures which contain 
data concerning the users of the application to prevent clients to have access 
to confidential clinical studies, the persons which represent all the staff in 
the hospital in order to have information about the investigators, the study 
nurses and other related people, ... To complete the database with useful data 
concerning clinical studies, new entity types were created and relationships 























Here is a complete description of the necessary structures and relations 
to respond to OP 'Study clients requirements through a logical schema, 
realized with DB-main, and a short description of each element : 
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The logical schema consists in 13 new entity types whose 10 are created 
and 3 are reused from the main database to complete the necessary data 
useful for the development of the module and its functionalities. Notice that 
the 10 new tables are prefixed with the characters STU_ to sort the tables in 
the main database. 
Each entity type is composed of 6 additional attributes which are use-
ful for tracing users operations and JPA technology . These attributes are 
• DELETED : mandatory number whose value equals 1 if the corre-
sponding record has been logically deleted. A logically deletion removes 
a record from the database without physically and definitively delete it. 
• DTECRE : creation date of the record. 
• DTEMOD : last modification date of the record. 
• NUMUSERCRE : identifying number of the user responsible of the 
creation of the record. 
• NUMUSERMOD : identifying number of the user responsible of the 
la8t moctifü:atiou of the record. 
• ROWVERSION : record number useful for JPA technology which in-
creases automatically the number when a new record is inserted in the 
corresponding table. 
Here is the description of each entity type and other personal attributes : 
ETUDE : entity type which stores data concerning the protocol of the 
corresponding clinical study and general information about the study. 
• NUMETU : technical and numeric identifier of the table. 
• NUM_EUDRACT : Eudract or Belgian number of the clinical study. 
• NUM_ETUDE_CEC : number given to identify the clinical study 
by the central ethics committee. 
• NOM_COURT : short name given to the clinical study introduced in 
t he protocol. 























• PATHOLOGIE : pathology of the patients to include in the clinical 
study. 
• NBR_PATIENTS : number of patients to enrol in the clinical study. 
• OUVERTURE_RECRUTEMENT : official date of the beginning 
of patients enrolment. 
• FERMETURE_RECRUTEMENT : official date of the end of pa-
tients enrolment. 
• INTERVENTIONNELLE : number to identify a interventional clin-
ical study. 1 if the treatment associated with the study required an 
intervention; 0 otherwise. 
• OBJECTIF : objective of the clinical study given in the protocol. 
• FIRME : firm or sponsor responsible of the clinical study application. 
• PERSONNE_CONTACT : contact person in the firm or sponsor. 
• NUMORC : icleutifier uurnber of the Cliuical Research Orgauism 
(CRO) responsible of the clinical study. 
• NUMSTE : identifier uumber of the curreut diuical study state. 
• NUMSERVICE : identifier number of the hospital service responsible 
of the clinical study. 
• NUMCE : identifier number of the central ethics committee associated 
with the clinical study. 
PATIENT_ETUDE: entity type which stores data concerning the patients 
included in clinical studies. Notice that personal information about patients 
are stored in the existing entity type PATIENTS in the main database. It is 
bound to this new entit:v type through a foreign key towards the identifier of 
the corresponding structure. 
• NUMPAT : technical and numeric identifier of the table. 
• NUMPATMIMS : identifier of the corresponding patient in the table 
PATIENTS. 
• DATE_CONSENTEMENT: optional date when the patient signed 























• DATE_RANDOMISATION : optional date when the patient has 
passed the randomization phase of the clinical study. 
• DATE_DEBUT_SCREENING : optional date when the patient 
has started the screening phase of the clinical study. 
• DATE_FIN_SCREENING : optional date when the patient has 
finished the screening phase of the clinical study. 
• DATE_DEBUT_TRAITEMENT: optional date when the patient 
has started the t reatment phase of the clinical study. 
• DATE_FIN_TRAITEMENT: optional date when the patient has 
finished the treatment phase of the clinical study. 
• DATE_FIN_SUIVI : optional date when the patient has finished the 
monitoring phase at the end of the clinical study. 
• NUMSTP : identifier number of the curreut patient state in the cliuical 
state. 
• NUMETU : ident ifier number of the clinical study in which t he patient 
is enrolled. 
EXAMEN : entity type which stores data concerning all types of possible 
examinations made on patients included in clinical studies. 
• NUMEXA : technical and numeric identifier of the table. 
• NOM_EXAM : name of the exam. 
• NUMPERS : identifier number of the care provider responsible of the 
exam. 
• EXAM_DATE : date and time when the examination occurs . 
• KIT_LABO : number which represent the necessity of a laboratory kit 
for the exam. 1 if a laboratory kit is necessary; 0 otherwise. 
• NUMP AT : identifier of the correspondiug patient iu the table PA-
T IENT_ETUD E. 
• NUMSERVICE identifier of the corresponding service where the 
exam takes place. 
INVESTIGATEUR_AIDE : entity type which stores data concerning the 























• NUMINV : technical and numeric identifier of the table. 
• NUMETU : identifier number of the clinical study in which the person 
is attached. 
• INVEST_AIDE : number to identify the person as an investigator or 
as another person. 0 if the person is an investigator; 1 otherwise. 
• NUMPERS: identifier number of the person in the table PERSONNES 
which permits to have information about that person. 
CRITERE_INCL_EXCL : entity type which stores data concerning the 
inclusion and exclusion criteria for the patients to enrol in clinical studies. 
• NUMCRI : technical and numeric identifier of the table. 
• NOM_CRITERE : full name of the criterion. 
• NUMETU : identifier number of the clinical study corresponcling to 
the criterion. 
• INCL_EXCL : number to identify if the record is an inclusion or an 
exclusion criterion. 0 if the record is an inclusion criterion; 1 otherwise. 
TRAITEMENT : entity type which stores data coucerniug the differeut 
treatments and bound medications or devices tested in clinical studies. 
• NUMCRI : technical and numeric identifier of the table. 
• NUMETU : identifier number of the clinical study in which the treat-
ment is realized. 
• NUMHIS : identifier number of the medication corresponding to the 
treatment. 
STATUT_ETUDE : entity type which stores the clifferent possible states 
of a clinical study : . 
• NUMSTE : tedrnical au<l 1mrrH-'ric identifier of the table. 
• STATUT : full name of the state. 
STATUT_PATIENT : eutity type which stores the differeut possible states 
of a patient enrolled in a clinical study : . 























• STATUT : full name of the state. 
ORC : entity type which stores the different Clinical Research Organisms 
(CROs) responsible to manage the clinical studies. 
• NUMORC : technical and numeric identifier of the table. 
• NOM_ORC : full name of the CRO. 
COMITE_ETHIQUE : entity type which stores the ethics committees of 
the hospitals which decide of the agreement to realize a clinical study in the 
corresponding site. 
• NUMCE : technical and numeric identifier of the table . 
• NOM_ COMITE_ETHIQUE : full name of the ethics commit tee. 
Such new database structures were necessary to realize the module concerning 
the administrative management of clinical studies. However, the creation of 
new tables and relationships, and the adaptation of the database is required 
to continue the project in order to complete the component realized during my 
internship but especially to pursue the development of the module concerning 
the second cornponent to support the scientific aualysis of clinical studies data. 
2. 3 Development of the module 
The developrneut of the first compoueut of OP'Study cousisted in the creatiou 
of an user interface which permits to realise basic operations of t he clinical 
studies data, namely CRUD fonctions (create, read, update and delete) on 
clinical studies, on patients enrolled in such studies and on all types of exam-
inations realized on these persons. According to the requirements collected 
following meetings with future usern in the hosµital of Mont-Godinne, different 
constraints were introduced concerning the realization of such an interface. 
Drafts of the future application view were established and presented to the 
clients to represent their needs in the best way. Once the final version of the in-
terface accepted, the development of the module and its operations could start. 
Mims Java cell offers a generic archetype to automatically produce a ba-
sic structure in layers for new modules. OP 'Study has been created using 
that archetype to create the module according to the layers of the application 
servers structure presented above. Therefore, the project established contains 























Furthermore, the archetype permit ted to implement different Maven configu-
ration files to manage dependencies between the sub-modules and other exter-
ual libraries, application coutext files to coutrol Spring options in the project , 
and Java classes and interfaces to realize basic operations through the different 
sub-modules. For example, it created data access abjects which enable basic 
operations on the database data . 
2.3.1 OP'Study structure 
The structure of the module fiually coutaiu · the 7 sub-mo<lules which rep-
resent the different layers of the architecture, a package with SQL database 
code for the new structures established, a Maven configuration file to manage 
all the necessary dependencies in the project as well for the relations between 
the sub-modules as for the interdependences with external libraries. These are 
available in the local Maven dependencies repository and achievable directly 
from a package in the project . 
1:1- · op-study 
+ C:. op-study-beans 
+ l:à op-study-business 
+ ti1I op-study-embedded 
+ ti1I op-study-fac.ade 
+ l:à op-study-rest 
+ l:à op-study-rest-client 
+ l:à op-study-view-javafx 
+ rtJ SQl 
m pom.xml 
External libraries 
Figure 4.2: OP 'Study structure 
The sub-module op-study-beans contains the beans created with Hibernate 
and JPA2 technologies, in charge of the object-relational mapping between 
Java beans and database structures. It represents the JPA entities layer in 
the established infrastructure. 
Data access and business abj ects layers are provided in the op-study-
business sub-module in two diffe rent underlying packages , both as well for the 
interfaces as for implementation classes . 
The business facade layer is introduced in the development through 2 dif-























interfaces for the <lifferent necessary abjects for local use, without web services. 
Such interfaces are implemented in the sub-module op-study-embedded. On 
the other hand, OmniPro modules work generally with remote access between 
the user interface and the database data, using web services. This approach 
is possible using rest web services developed in op-study-rest if an inter-
mediate web application is necessary and op-study-rest client to implement 
the interfaces offered in the second package of the op-study-facade sub-module. 
The sub-module op-study-view-javafx contains the implementation of the 
final user view, using J avaFX teclmology. The developecl interfaces are bouml 
with other layers using the interface of the sub-module op-study-facade, 
implemented in the sub-module op-study-embedded for local development 
of the application. The view code is divided in two parts contained in two 
packages : the interface code using fxml files and the controllers code in Java. 
The development of sub-modules and the explanations about configura-
tion files will be explained in the next snb-sections. It is important to not ice 
that a Maven configurat ion file (pom.xml) and an application context file are 
automatically created in each sub-module, using the archetype, to manage 
respectively the dependencies and Spring options in each sub-module. 
2.3.2 Sub-modules structure 
op-study-beans i11troduces the differe11t beans created for the manipulat ion 
of database data through the operations provided by Hibernate and JPA2 
technologies. These beans are created according to object-relational mapping 
provided by Hibernate and using annotations to bind the abjects and their 
attributes to database tables and columns. Annotations permits to avoid dif-























- 1:. op-study-beans 
- tJ src 
0--1:J main 
- l:J java 
0--1!:J be.mims.study.bean 




c 'à lnvestigateurAide 
c 'à OrganismeRechercheClinique 
c 'à PatientEtude 
StatutEtude 
StatutPatient 
c 'à Traitement 




Figure 4.3: Beans module structure 
The beans defined here are suffi.cient to manage administratively clinical 
studies as they represent all the new entity types added to the database. How-
ever , other abjects are necessary and available in Mims external libraries to 
have information about existing structures and data, such as the data about 
the medical staff and the different services in the hospital. Here is an example 
of the beau defini tion, repret:ïeutiug the cliuical t:ïtudie::; data : 
1 package be.mims.study.bean; 
2 
3 //Imports 
4 // .. . 
5 
6 ©Entity 
1 ©Table(name = "STU_ETUDE") 











©SequenceGenerator(name = "PKS_STU_ETUDE", allocationSize = 1, 
sequenceName = "PKS_S·TU_ETUDE") 
©GeneratedValue(generator = "PKS_STU_ETUDE", strategy = 
Generationîype.SEQUENCE) 
©Column(name = "NUMETU") 
private Long numEtude; 
©Column(name = "NUM_EUDRACT") 





19 ©Column(name = "NUM_ETUDE_CE") 
1 20 private String numEtudeCE; 21 
22 ©OneToOne(cascade = CascadeType .REFRESH, fetch FetchType.EAGER, 
1 
optional = false) 
23 ©JoinColumn(name = "NUMCE") 
24 private ComiteEthique CE; 
25 
1 26 ©OneToOne(cascade = CascadeType.REFRESH, fetch = FetchType . EAGER, optional = false) 
27 ©JoinColumn(name = "NUMORC") 
1 
28 private OrganismeRechercheClinique ORC; 
29 
30 ©Column(name = "NOM_COURT") 
31 private String nomCourtEtude; 
1 32 33 ©Column(name = "NOM_COMPLET") 
34 private String nomCompletEtude; 
1 
35 
36 ©Column(name = "PATHOLOGIE") 
37 private String pathologie; 
38 
1 39 ©Column(name 
Il NBR_PA TIENTS Il) 




43 ©Column(name = "OUVERTURE_RECRUTEMENT") 




47 ©Column(name = "FERMETURE_RECRUTEMENT") 
48 private Date fermetureRecrutement; 
1 
49 
50 ©Column(name = "INTERVENTIONNELLE") 
51 private boolean isinterventionnelle; 
52 
1 
53 ©Column(name = "OBJECTIF") 
54 private String objectif; 
55 
56 ©Column(name = "FIRME") 
1 57 private String firme; 58 
59 ©Column(name = "PERSONNE_CONTACT") 
1 
60 private String personneContactFirme; 
61 
62 ©OneToOne(cascade = CascadeType.REFRESH, fetch FetchType.EAGER, 
1 
optional = false) 
63 ©JoinColumn(name = "NUMSERVICE") 
64 private Personne service; 
65 
1 
66 ©OneToOne(cascade = CascadeType.REFRESH, fetch FetchType.EAGER, 
optional = false) 
67 ©JoinColumn(name = "NUMSTE") 
68 private StatutEtude statutEtude; 
1 69 70 ©Column(name = "DELETED") 

















































©Column(name = "DTECRE") 
private Date dateCreation; 
©Temporal(TemporalType.TIMESTAMP) 
©Column(name = "DTEMOD") 
private Date dateModification; 
©Column(name = "NUMUSERCRE") 
private Long numUserCreation; 
©Column(name = "NUMUSERMOD") 
private Long numUserModification; 
©Version 
©Column(name = "ROWVERSION") 
private Long rowVersion; 
IIConstructors, getters and setters 
11 ... 
Notice that the beans extend the class BaseEntity<T> which permits to imple-
ment the Identifiable interface allowing generic fonctions to manage identifiers 
in these beans, and the Auditable interface which provides a mean to create 























op-study-business is composed of two main packages which represent 
respectively the data access and the business abjects layers. These packages 
are composed of Java interfaces and their implementation classes. The DAO 
package provides functionalities for the management of database data, using 
the beans defiue<l in the op-study-beans sub-module. The business operations 
are provided in the BO package to realize common and useful tasks, reusable 
by different abjects in the upper layers, such as the verification of regular 
expressions in the different controls of the interfaces . Here is the structure of 
the sub-module : 
- til op-rtudy-business 
tJ src 
Ëf-1:J main 
- tJ java 
Ëf-1:J be.mims.study.business 
- 1:J bo 
1:J impl 
'à ComiteEthiqueBOlmpl 
c 'à Critere!nclExclBOlmpl 
c 'à EtudeBOlmpl 
c 'b ExamenBOlmpl 
c 'à InvestigateurAideBOlmpl 
c 'à OrganismeRechercheCliniqueBOimpl 
c 'à PatientEtudeBOlmpl 
c 'b StatutEtudeBOimpl 
c 'à StatutPatientBOlmpl 
c 'à TraitementBOlmpl 
t 'à ComiteEthiqueBO 
• 'à Critere!nclExclBO 
l 'à EtudeBO 
• 'l, ExamenBO 
l 'à lnvestigateurAideBO 
I 'b OrganismeRechercheCliniqueBO 
!) 'b PatientEtudeBO 
r "à StatutEtudeBO 
!) 'b StatutPatientBO 
l 'à TraitementBO 
1:J dao 




- til op-study-business 
- tJ src 
Ëf-1:J main 




- l:J jpa2 
c 'à ComiteEthiqueDAOimpl 
c 'à CriterelnclExclDAOlmpl 
c 'à EtudeDAOlmpl 
'à ExamenDAOlmpl 
'à lnvestigateurAideDAOlmpl 
C 'à OrganismeRechercheCliniqueDAO!mpl 
'à PatientEtudeDAOlmpl 
'à StatutEtudeDAOlmpl 
C 'à StatutPatientDAO!mpl 
ô TraitementDAOlmpl 
I "à ComiteEthiqueDAO 
i ô CriterelnclExclDAO 
'à EtudeDAO 
Î ô ExamenDAO 
I 'à lnvestigateurAideDAO 
9 'à OrganismeRechercheCliniqueDAO 
r 'à PatientEtudeDAO 
1 'à StatutEtudeDAO 
1 'à StatutPatientDAO 
1 'à TraitementDAO 
- Ci resources 
G-1:J be.mims.study.business 
L ': applicationContext.xml 
m pom.xml 
Figure 4.4: Data access and business abjects modules structure 
Agaiu, and for all sub-rnodules, a Maven configuration file (pom.xml) and 
an application context file (applicationContext.xml) are available to configure 























op-study-facade contains the clifferent interfaces available for the 2 de-
velopment paradigms : local and remote developments; the second uses REST 
web services betweeu the fiual user interface aud BF layer to use rernotely the 
application. Here is the structure of the sub-module : 
- Là op-study-facade 
- LI src 
8-LI main 
- LI java 
8- l!'.:l be.mims.study.faca.de.bf 
- l!'.:l rest 
l 'à ComiteEthiqueBFRest 
t 'à CritereinclExclBFRest 
1 'à EtudeBFRest 
r 'à ExamenBFRest 
l 'à InvestigateurAideBFRest 
r 'à OrganismeRechercheCliniqueBFRest 
t 'à PatientEtudeBFRest 
l 'à StatutEtudeBFRest 
I 'à StatutPatientBFRest 
l 'à TraitementBFRest 
I 'à ComiteEthiqueBF 
1 'à CritereinclExclBF 
r 'à EtudeBF 
1 'à ExamenBF 
t 'à InvestigateurAideBF 
1 'à OrganismeRechercheCliniqueBF 
1 'à PatientEtudeBF 
t 'à StatutEtudeBF 
I 'à StatutPatientBF 
t 'à T raitementBF 
+ ~ resources 
m pom.xml 
Figure 4.5: Business facade module structure 
The package containing REST interfaces is implemented in op-study-rest-
client, and in op-study-rest sub-modules if the application needs an interme-
diate application server between the client view and the BF layer. The imple-
mentation of the BF layer interfaces were implemented during t he internship 























op-study-embedded is the sub-module providing the implementation 
classes for the op-study-facade sub-module interfaces without web services. 
The implementation of REST interfaces are not explained here as they were 
not used during the internship. Here is the structure of the sub-module : 
- 1:. op-study-embedded 
- LJ src 
0-- LJ main 
- LJ java 
B--1!:J be.mims.study.embedded.bf 
c 'à ComiteEthiqueBFimpl 
c 'à CritereinclExclBAmpl 
c 'à EtudeBFimpl 
'à ExamenBFimpl 
c 'à ln.vesti:gateurAîdeBFimpl 
.c 'à OrganismeRechercheCliniqueBFimpl 
c 'à PatientEtudeBFimpl 
c 'à StatutEtudeBFimpl 
c 'à StatutPatientBFimpl 
c 'à TraitementBFimpl 
- wi resources 
B--1!:J be.mims.study.embedded 
L ...._ a.pplicationContext.xml 
m pom.xml 
























op-study-view-javafx sub-morl.ule provides all the necessary files to cre-
ate the interfaces, using JavaFX technology. Here is the structure of the sub-
module: 
- t:i\ op-study-view-javafx 
- 1:J src 
B-1:J main 
+ 1:J deploy 
- 1:J java 
8- 1!:J be.mims.study.view.javafx 
- 1!:J controllers 
c 'à AjoutExamenController 
c 'à AjoutPatientController 







c 'à ModificationPatientController 












- 1!:J utils 
L c 'à Applmages 
c 'à LoginFrame 
c 'à OpStudy 
c 'à StudyMain 
- Oi resources 
- l!:J be.mims.study.view.javafx 
+ 1!:J CSS 





- 1!:J META-INF 
L : persistence.xml 
m pom.xml 























In this sub-module, 2 main packages are created , one containing the source 
files for the creation of the interfaces and main classes , and the second which 
i11troduces the resources files to configure the interfaces. the security to log i11 
the application and a persistence file to declare the connection to the database. 
Firstly, the sources files are present d in 2 general packages which con-
tain respectively the controller classes to manage user actions on the interfaces 
and the fxml files which consist in the physical declaration of the interfaces 
elements. Other Java classes are provided , they are useful to launch the appli-
cation and the two first frames, namely the login and the main menu interfaces. 
Secondly, the resources files necessary to manage users views opt ions and the 
connection to the application and the database are introduced. The CSS pack-
age contains the files to personalize the interfaces elements . The package also 
provides images included in the img package, used in the application to make 
the interfaces attractive. Application context files are provided to declare the 
login options, either for local connection to the database ( dummy. xml file) or 
fo r remote connectiom; through web services (OmniPro.xml file). The appli-
cation context file contains basic information to manage Spring opt ions in the 
sub-module. Furthermore, a persiste11ce file is offered to cleclare the options 
for the connection to the database. 
2.3.3 Configuration files structure 
111 tlüs sub-sectio11 , the structure of differe11t coufiguratiou files will be pre-
sented , it concerns the Maven (pom.:xml) , the application context (application-
Context.xml) and the persistence (persistence.xml included in the op-study-
view-javafx sub-module) configuration files. 
Maven configuration files contain the description of the necessary depen-
dencies in each module and sub-module. It permits to bind the external li-
braries and modules to the project , through dependency injection at the com-
pilation of the module. These files also introduce other information about the 
module, such as coordinates as explained in the chapter 3, build settings , the 
underlying and the parent modules, and other information about the environ-
ment and the properties of the proj ect. However we focus here in dependencies 























Here is the incomplete code of the configuration file (Maven pom.xml) for 
the management of J avaFX sub-module propert ies : 
1 <?xml version="1.0" encoding="UTF-8"?> 
2 <project xmlns="http://maven.apache . org/POM/4.0.0" xmlns :xsi="http : //www . 
w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http : //maven. 
apache.org/POM/4 .0.0 http : //maven.apache . org/xsd/maven-4 . 0 . 0 .xsd"> 
3 <mode1Version>4.0.0</mode1Version> 
4 










15 <version>l.0 . 0-SNAPSHOT</version> 
16 </parent> 
17 
18 <!-- Properties of the module--> 
19 <properties> 
20 <!--Java FX properties--> 
21 <j avafx. lib . ant-j avafx. j ar>${j ava. home}/ .. /lib/ant-javafx. jar</ j avaf x 
. lib .ant-javafx.jar> 
22 <applet .width>1920</applet .width> 
23 <applet.height>1080</applet.height> 




21 <!-- Dependencies with external libraries and other modules--> 
u <dependencies> 






~ </ dependency> 



































The Maven configuration file definet:> th coor<linatet:>, the parent , propertiet:> for 
the application view and dependencies with other sub-modules and necessary 
external libraries such as ojdbc7 to manage the operations on the database. 
Spring application context files permit to configure Spriug options 
in the modules. Spring brings benefits in such an application; for example, it 
provides a mean to build beans without instantiating nor initializing them in 
the code, to inject instructions in the production code, to define links between 
the independent sub-modules, . . . as well in defining these options in the 
application context fil et:> at:> t:>ometimet:> direct ly in the production code. Here 
is the application context file (applicationContext.xml) for the configuration 
of Spring options in the op-study-view-javafx sub-module : 
1 <?xml version="l.0" encoding="UTF-8"?> 
2 <beans xmlns="http://www.springframework.org/schema/beans" 
3 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
4 xmlns:context="http://www.springframework.org/schema/context" 
xmlns:tx="http://www .springframework.org/ schema/tx" 
5 xmlns:task="http://www . springframework . org/ schema/task" xmlns: 
asycn="http://www .springframework . org/schema/tx" 
6 xsi : schemaLocation= "http://www.springframework . org/schema/beans 
http://www . springframework.org/schema/beans/spring-beans.xsd 
http://www.springframework.org/schema/context http : //www . 
springframework.org/schema/context/spring-context.xsd 
7 http://www.springframework.org/schema/tx http://www .springframework . 




g < 1-- Embedded application context and local login options retrieving 
--> 
10 <import resource=" classpath: be/mims/ study / embedded/applicationContext . 
xml"/> 
11 <import resource=" applicationContext-securi ty-dummy. xml" /> 
12 
13 <!-- Definition of the context for the annotation of beans in the code 
--> 
14 <context: annotation-config/> 
15 <context: component-scan base- package="be .mims. study. view. javafx" /> 
1G <task:annotation-driven /> 
11 <asycn:annotation-driven /> 
1s <tx:annotation-driven/> 
19 
20 <!--Entity and transaction injection--> 
21 <bean id=" enti tyManagerFactory" class=" org. springframework . orm. j pa. 
LocalEntityManagerFactoryBean"> 
22 <property name="persistenceUnitName" value="studyJfx"/> 
23 </bean> 
24 
2s <bean id="transactionManager" class=" org. springframework. orm. jpa. 
JpaTransactionManager"> 

























T he applir.at. iou r.out.ext. file r.outaim; the <lefiui t iou of a ent. ity manager far.tory 
bean which will be used in the persistence file defined hereafter ; it is used 
to realize the persistence operations in the database. It provides also a 
mean to define new beans in the code with annotations and imports options 
from another configuration file to manage login parameters and embedded 
application context information. 
Persistence configuration file configures the pernistence unit to real-
ize operations on the database; it retrieve the bean defined for this purpose 
from the applir.at iou r.outext file. The file also r.outaius the <lefiuitiou of 
the necessary beans in the sub-module, as well the external abjects as 
those defined in the op-study-beans sub-module; permitting their use in 
the code. Furthermore, the configuration of the persistence file enables the 
definition of the database parameters to connect to the database. Here is the 
pernistence.xml file contained in th op-study-view-j avafx sub-moclule : 
1 <?xml version="l.0" encoding="UTF-8"?> 
2 <persistence version="2.0" xmlns="http://java.sun . com/xml/ns/persistence" 





s <persistence-unit name="studyJfx" transaction-type="RESOURCE_LOCAL"> 
6 




























<!-- Declaration of external beans used --> 
<class>be.mims.commons.bean.Patient</class> 
<class>be.mims . commons.bean.Personne</class> 
<class>be.mims.commons .bean.Medication</class> 
<class>be.mims.commons.bean.UtilisateurServicePK</class> 
<!-- Declaration of the beans defined in the op-study-beans module 
--> 
















1 36 37 
38 
1 39 40 
41 

















<class>be.mims . study.bean.Examen</class> 
<class>be.mims.study.bean.InvestigateurAide</class> 
<class>be.mims.study.bean.OrganismeRechercheClinique</class> 
<class>be .mims . study . bean . PatientEtude</class> 
<class>be.mims.study.bean . StatutEtude</class> 
<class>be.mims.study.bean . StatutPatient</class> 
<class>be.mims.study.bean.Traitement</class> 
<!-- Properties to define the connection to the database --> 
<properties> 
<property name="hibernate.dialect" value= "org.hibernate .dialect. 
OraclelOgDialect"/> 
<property name="hibernate .max_fetch_depth" value="3"/> 
<property name="hibernate.show_sql" value="false"/> 
<property name="hibernate . format_sql" value="false"/> 
<property name="javax .persistence.jdbc.url" value="valueOfîheUrl"/> 
<property name="javax.persistence.jdbc . user" value="valueOfîheUser" 
/> 
<property name="javax.persistence.jdbc.password" value=" 
valueOfîhePassword"/> 




























Clinical studies data reporting 
1 Situat ion 
The objective of the researches on CDISC documentation was to find a 
standard or a protocol for exchanging clinical studies data, in order to 
transmit this information automatically to studies sponsors, directly from 
the collection of these data in the database related to OP 'Study module. 
Therefore, researches on the documentation provided by the organization 
were made at the end of the internship and after, to find a international and 
recognized model for the submission of clinical studies data to sponsors of 
such studies. 
CDISC is an international organization that has established standards to 
support the acquisition, exchange, submission and archive of clinical research 
data and metadata. However, the association was initially stopped to the 
specification of such standards and not their implementation. Gradually, 
it still provided to its members , and then to the public, guides for the 
implementation of such specifications. 
Nowadays, CDISC offers a few implementation guides publicly to explain 
the use and the creation of datasets which contains clinical studies data. Other 
guides are probably provided by the organization, but requires a company 
membership to contribute to their researches , and obtain full access to the 
documentation of the standards. However, CDISC website provides freely 4 
implementations guides : 
1. The Study Data Tabulation Model Implementation Guide for Human 
Clinical Studies (SDTMIG) 
























3. The Study Data Tabulation Model Implementation Guide for Medical 
Devices (SDTMIG-MD) 
4. The Study Data Tabulation Model Associated Persons Implementation 
Guide (SDTMIG-AP) 
Examples will be given in the next sub-sections to represent the creation of 
datasets for the reporting of clinical studies results and data. Next, results 
and interpretations will be proposed to summarize the activities to answer the 
research question which introduced this report : "Are there any standards, 
international protocols which allow automatic submission of clinical study re-
sults and data to the sponsors of these studies ?" Finally, critics will be raised , 
as well positive as negative, against CDISC organization and its standards. 
2 Implementation of datasets 
Researches and analyses were realized on the implementation guides provided 
by the organization to understand the modelling and the implementation 
of clinical studies data in datasets for the reporting. Therefore, The Study 
Data Tabulation Model Implementation Guide for Human Clinical Studies 
(SDTYIIG) proposes a cornplete docurne11tatio11 to u11dnstaud the differeut 
general domains representing clinical studies data and the corresponding 
variables in the underlying datasets. The guide is very general but proposes 
different examples to gather data in datasets , as well for clinical studies 
protocols information as for the data of these studies. However, much more 
accurate examples are provided in the other guides (SENDIG, SDTMIG-MD 
and SDTMIG-AP) to store clinical studies data in datasets. 
Examples will be introduced in the 2 next sub-sections to present firstly the 
representation of clinical studies protocols information in such data structures 
using SDTMIG documentation, before introducing the creation of datasets 
containing the studies data, focusing on the interesting SDTMIG-AP guide. 
These examples will be suffi.dent to understand the creation of datasets for the 




















Most of the observations gathered during the clinical studies can be represented 
according to one of the three SDTM main observation classes : Interventions, 
Events or Findings. 
• The Interventions domain collects investigational , therapeutic and other 
treatments that are administered to clinical studies subjects , as definedin 
the study protocol of the study. It also contains actual or expected 
physiological effect due to the substances received. 
• The Events class gathers planned protocol important stages in clinical 
studies progress such as randomization and study completion, but also 
occurrences, conditions or incidents independent of planned evaluations 
which occur during the study or before. 
• The Findings class stores the observations which result from tests or 
evaluations. For example, it contains data such as laboratory tests, body 
weights, food and water consumption, clinical observations, . .. Usually, 
the Findings general observation class collects the majority of data, typ-
ically consisting in measurements or responses to tests, at specific time 
points. 
Each of these domain provides a large range of variables to represent all 
corresponding types of studies data. 
In addition to the main observation classes, special purpose datasets are 
often included in submissions to sponsors, containing specific standardized 
structures to represent additional study or protocol data and metadata. For 
example, the Domain datasets, consisting of Demographics (DM) , Comments 
(CO) , and Subject Elements (SE) . Such datasets include information which is 
not conform to one of the three main observation classes. Another examples 
are Study Design Model (TDM) datasets, composed of Study Elements (TE), 
Study Arms (TA), Study Sets (TX) and Study Summary (TS), offering 
information about the study design of clinical studies protocols. Furthermore, 
datasets are provided to represent the relationships between the datasets, 
contained in Relationship datasets. 
In this sub-section, we will focus on the data concerning clinical studies 
protocols, particularly concerning the Studies Arms (TA) of the study design. 
In the next example, we will assume a simple sponsor-defined protocol which 



















be screened for 7 days before the randomization into three protocol groups, 
defined as : 
• Group 1 is a control group of 20 subjects , 10 male and 10 female, dosed 
with vehicle once per day for 28 days, 
• Group 2 is a low-dose group of 20 subjects, 10 male and 10 female, dosed 
at 100 mg/kg once per day for 28 days, and 
• Group 3 is a high-dose group of 20 subjects , 10 male and 10 female, 
dosed at 500 mg/kg once per day for 28 days. 
In this case, the study design consists of 3 Study Arms , as there are 3 distinct 
sets of elements : 
Screening / Treatment 
1 . 
2. 100 mg/kg 
3. 
Figure 5.1: Representation of the different possible arms of the treatment 
These Studies Arms can be represented in a file, in a tabular form for the 
submission. Here is the visual representation of the dataset : 
a .... STUDYID DO!IJAIN ARMCD ARM TAITORD ETCD ELBIL"i'T 
1 EXP! TA 1 SCRN Ser= lùndouuzed to 
2 EXPI TA TilTOI Vehicle Control 
EXP! TA SCRN" Scttt11 
4 E.XPI TA TilT02 100 mg,k g Dtug A 
EXP! TA SCR.'1 Scrttn lùndom=d to GToup J 
EXPI TA TilTOJ 500 mg kg Drug A 
Figure 5.2: Example of a dataset represent ing study arms information 
Variables are used to define the clifferent types of value in the dataset 
STUDYID is a unique identifier for a study, DOMAIN is a two-character 
abbreviation for the domain, ARMCD is a planned Arm code to identify 
the Arm number , ARM is a descriptive name given to a pecific Study 






























record in the dataset) within an Arm, ETCD is the short name of the 
Element used for programming and sorting, ELEMENT is the name of 
the Element, TABRA CH is a condition met , occurring at the end of an 
Element, which cause an Arm to branch off from other Arms, and EPOCH is 
the name of the study Epoch with which this Element of the Arm is associated. 
With the different domains provided and their variables, it is possible to 
represent all types of data, as well for protocol information (in particular , the 
study design in this example) as for clinical studies results and data. 
2.2 SDTMIG-AP 
In the previous sub-section, we presented the datasets used to represent 
clinical studies protocols information. In this part , the creation of datasets for 
clinical studies data and results will be explained with examples provided in 
the Study Data Tabulation Model Associated Persons Implementation Guide 
(SDTMIG-AP). 
Different studies collect data about external persons (not the subject under 
study). Those persons can be associated with the study itself, a particular 
study subject , or a <levice use<l in the stu<ly. The tenn "Associated Persons ': 
is used to classify the non-subject participants in a clinical study. The 
relationship that an Associated Person (AP) has with a study subject is often 
the reason for collecting data about that particular person. For example, a 
study concerned with family history may collect data about paternal relatives , 
spouses, or children. Another study could need to know how a disease is 
affect ing the subjects in terms of "caregivers" quality of life. In both cases, 
the nature of the relationship that these persons have to subjects in the study 
is a determining factor in collecting data about them. 
SDTMIG-AP is intended to guide the organization, the structure of 
datasets, and the format of data collected about persons who are not subjects 
of a study. These standard datasets are suitable for the submission of data to 
a regulatory authority or a sponsor. 
The following examples show the structure of the data collected in 
datasets for the AP domain. Firstly, an example of AP medical history will be 
presented to explain how family history data can be collected in datasets for 
the submission. Then, laboratory test results from study subject associated 
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- - - - - - -
Rows 1-16: MH data abou1 th,, subject's father. 
Rows 17-35: MH data about the subject's father ' s family. 
Row STUD\lD DOM..\IN .U'ID MBSEO RM,llJID SllL 
1 A1999 APMH A1999-123 1 A1999.031 FATHER, B!OLOGICAL 
1 A1999 APMH Al999-l23 ~ A1999.031 FATHER, BIOLOGICAL 
l Al999 APMH A1999-123 J A1999.0ll FATHER, BlOLOGICAL 
4 AIY!III ,,.n111 Al9!111-ll3 4 A1999.u31 ,A111ER, Btul CJUJLAl 
5 Al999 APMH A1999-123 j A1999.031 FA THER, BIOLOG !CAL 
6 Al999 APMH Al999-12l 6 A1999.031 FATHER, BIOLOGICAL 
7 A1999 APMH A1999-123 1 A1999.03! FATiiER. BJOLOGICAL 
s A1999 APMH A1999-123 s A1999.0ll FATHER, BIOLOGICAL 
g A1999 AnlH A!999-123 9 A1999.03 1 FATHER, BJOLOGICAL 
10 A1999 APMH Al999-123 10 A1999.0l l FA THER, BlOLOG !CAL 
Il AIY!I\I AP:!.111 A1999-Ll I l A1999.031 <A111= i,!m c>GICAI 
11 A1999 APMH A1999-12l 12 A1999.0ll FATHER, B!OLOG!CAL 
u A1999 APMH A1999-12l 14 A1999.0l l FATHER, BIOLOGICAL 
u A!999 APMH A1999-123 Il A1999.0ll FATHER. BIOLOG!CAL 
i; A!999 APMH A1999-123 16 A1999-0ll FATHER. BIOLOGICAL 
16 A1999 AP~lH A1999-113 Il A _l OQQJH. 1 FA' M .. 
17 Al999 APMH Al999-G02 1 A1999.0l l RELATIVE OF FATHEP, BIOLOG!CAL 
18 Al999 APMH A1999-G02 2 A!999.0JI RELATIVEOFFATHEP.,BIOLOG!CAL 
19 A1999 APMH AJ999-G02 J Al999-0J I RELATIVEOFFATHEP.,BIOLOGICAL 
20 A1999 APMH A1999-G02 4 A1999.031 RELATIVEOFFATIŒR, BIOLOGICAL 
21 Al999 APMH Al999-G02 j A1999.0l l RELATIVE OF FA THEP., B!OLOGICAL 
11 AI999 AnlH AJ999-G02 6 A1999.031 RELATIVE OF FATHER. BlOLOGICAL 
23 A1999 APMH A1999-G02 1 A1999.031 RELATIVE OF FATIŒK. BIOLOG!CAL 
14 Al999 APMH A1999-G02 8 A1999.0ll RELATIVEOFFATHEP.,BIOLOGICAL 
25 Al999 APMH A1999-G02 9 A1999.031 RELATIVE OF FATIŒP., BIOLOG!CAL 
16 A1999 AP~Ol A1999-G02 10 A1999.03 1 RELATIVE OF FATHEP~ B!OLOG!CAL 
27 A1999 APMH A1999-G02 11 A1999.031 RELATIVE OF FATHEP., BIOLOGICAL 
28 A1999 AP}.Ol Al999-G02 12 A1999-031 RELATIVE OFF ATHEK BIOLOGICAL 
29 A1999 Al'l>Ol Al999-G02 11 A1999.031 RELATIVE OF FATHER. BIOLOGICAL 
30 A1999 APMH A1999-G02 18 A1999.03 1 RELUIVE OF FATHEP., BIOLOGICAL 
31 A1999 APMH A1999-G02 19 Al999.031 RELATIVEOFFATJŒKB!OLOGICAL 
32 A1999 APMH A1999-G02 13 Al999-031 RELAffi'E OF FATHEP, BIOLOG!CAL 
33 Al9!19 APM!i Al•-••• 14 Al• .. •n l ,c,. ~ .1v.C:Ot-f-A 1nrr-.... .  
3-1 A1999 APMH Al999-G02 Il A1999.0ll RELATIVE OF FA THEK BIOLOGICAL 
35 A1999 APMH A1999-G02 16 A1999.031 RELATIVE OF FATHEP, BIOLOGICAL 
- - - - - - - - - - -
1IHTEJW MHPRESP MHOCCLlt 
HEART DISEASE y N 
STROKE y N 
CA.>;CER y N 
Dtl'iu,»1< N y N 
DIABETES y N 
SEXUAll Y TRANS.MITTED DISEASE y u 
ALZHEIMER 'S DISEASE y N 
OBESITY y N 
BillIDNESS y N 
DEAFNESS y N 
ALI.ERG!ES y N 
ASTHMA y N 
CONGENITAL ABNOR.¼Al.lT!ES y N 
LEAR.'IING DlSABll.ITŒS y N 




HE.-.R.T DISEASE y N 
STP.OKE y N 
CANCER y N 
DEPRESSION y u 
DL>J!ETES y y 
SEXUALLY TRANSMITTED D!SEASE y u 
ALZIŒIMER'S DISEASE y u 
OBESITY y N 
BillIDNESS y N 
DEAFNESS y N 
ALI.ERGIES y N 
ASTID.!A y u 
CO!\GENTIAL ABNOP-¼Al.ITŒS y N 
LEAR."'1NG DISABll.ITŒS y u 
PSYCHOMOTOP. RETARDA TION y N 
SUBFERTll.ITYIINFERTILITY y N 
' 
y N 
STil.UllRTHS y N 
INFANTDEATHS y N 
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Variables are use<l to <lefine the different types of value in the dataset: 
STUDYID is a unique identifier for a study, DOMAIN is a two-character ab-
breviation for the domain, APID is an identifier for a single assoc.iated pernon, 
a group of associated persons, or a pool of associated persons, MHSEQ repre-
sents the order of an medical history record for an associated person, RSUBJID 
is an ident ifier for a related subject or pool of subjects, SREL describes the 
relationship of the associated person(s) identified in APID to the subject or 
pool identified in RSUBJID, MHTERM is the name of the medical history 
criterion, YIHPRESP and MHOCCUR are flags to know if the medical his-
tory criterion has respectively occurred for the associated persan ( or group of 























Associated Persons Laboratory Test Results ( APLB) sub-domain 
is part of the Findings main observation domain, and consists in the gathering 
of data about study subject associated persans laboratory results. In the 
following example, the study consists in the testing of a diagnostic medical 
device, which might be used hy blood banks to fiud out uudesirahle elemeuts. 
The machine test a pool of samples rather than each sample individually. The 
analysis results positive if there is a need for further testing. Here, the device 
responds with a positive and a negative result ; the positive one is tested with 
another device to confirm the answer and target the positive sample in the 
pool. 
Row l: Apooled sample with a positive result. 
Row 2: A pooled sample with a negative result. 
Rows 3-7: Data for the individualAPs from POOL! , tested with a differenl devic.e. 
Row 5nl>\1D DOM.UN APID LBSEO RDD1D SRIL LBORRES 
l ABC API.B POOLl 1 GR.i~OIJ DONOR, SAMPI.E POSITIVE 
2 ABC API.B POOU 1 GRNMOlJ DONOR, SAMPLI NEGATIVE 
3 ABC API.B APOOI 1 CKOOI DONOR, SAl\iPLE NEGATIVE 
~ ABC API.B AP002 2 CKOOI DONOR, SAMPLE POSITIVE 
5 ABC API.B AP003 3 CKOOI OONOR, SAMPU NEGATIVE 
6 ABC API.B AP004 4 CKOOI OONOR, SAMPLE NEGATIVE 
7 ABC API.B AP005 5 CKOOI OONOR, SAMPLE NEGATIVE 
Below is the POOLDEF table that defines POOLl and POOL2. 
Rows l -5: The individual associated persollS that make up POOLl. 
Rows 6-10: The individual associated persollS that make up POOL2. 
Row 5n'D\1D POOLID APID 
1 ABC POOL! APOOI 
1 ABC POOLl AP002 
3 ABC POOL! APUU3 
~ ABC POOL! AP004 
5 ABC POOL! AP005 
6 ABC POOU AP006 
7 ABC POOU AP007 
8 ABC POOU APOOS 
9 ABC POOU AP009 









Figure 5.4: Example of datasets representing associated persans laboratory 
test results sub-domain data 
The necessary variables to define the different types of value in the two 
datasets are : STUDYID is a unique identifier for a study, DOMAIN is a 
two-character abbreviation for the domain, APID is an identifier for a single 
associated person, a group of associated persans, or a pool of associated 
persans, LBSEQ represents the order of a laboratory result record for each 
associated person of group of associated person, RDEVID is an identifier 
for the related device, SREL describes the relationship of the associated 
person(s) identified in APID to the device identified in RDEVID , LBORRES 
is the value of the laboratory result, LBDTC is the laboratory test date, and 























The relationship between the related datasets in the example will be defined 
in the define.xml file (introduced in the state of the art section) which explain 
the relationships between the datasets contained in a submission. It is in fact 
a file which describes the metadata of the datasets. 
3 Results 
The submission of clinical studies data, through the use of CDISC standards 
consists in the creation of datasets; clefinecl in a tabular form. Such datasets 
are submitted in files intended for datasets, plus a define.xml file to describe 
the relationships between the datasets, and the general information about the 
gathering of such studies data. 
Therefore, CDISC provides a way to transmit clinical studies data easily 
to sponsors and regulatory authorities, in an international format. Sponsors of 
























4 Crit ics 
The process for the submission of clinical studies data through CDISC 
stanclanb consists in simple tabular files, with a clescription file for the 
relationships between these datasets. This activity brings different benefits, 
but also drawbacks. 
Concerning the benefits, CDISC provides a simple way to submit clinical 
studies information to sponsors, through the transmission of tabular files , 
created in an international format, permitting efficient use and analysis of 
machine and lmman-readable files. Fur thermore, the organization is widely 
widespread around the world , and the contributors are numerous , providing 
quality standards and documentation. 
CDISC st andards are complete and useful , but brings also drawbacks. 
Firstly, the quant ity, the precision and the quality of the variables offered 
for the defi.ni tion and the submission of clinical studies data in main observa-
tions classes, defi.ned in datasets, are disadvantageous as the process implies 
an excellent and complete knowledge of the data structures provided in the 
stanclards. Furthermore, such constructions permit to acld new variables clefi.-
nitions in personalized datasets to complete the list of available data structures, 
making the process of comprehension and analysis much more complicat ed for 
the sponsors. Finally, the organization offers a large range of standards with 
abundant documentation to describe a mean to submit clinical studies data to 
studies sponsors. The analysis of the process concluded in the activity of tab-
ulat ions creation, in a manner similar to the defini tion of database t ables and 
records. With an important influence in the world and a global participation 
of contributors, the results of the analysis of documentation may appeared 

























In this chapter , ideas for future works are presented. At first , an introduction 
to the remaining tasks to be carried out in the IFlec project will be proposed. 
In a second step, research ideas based on CDISC, will be introduced to support 
the automatic submission of clinical studies results. 
1 Administrative 
studies 
management of clinical 
As we have shown in the introduction, IFlec project consists in the develop-
ment of a software to monitor clinical studies. The module is implemented 
at:i two parts: the a<lministrative management of clinical stu<lies an<l scientific 
analysis of the results. The first component was performed according to 
the objectives and requirements set. The application can perform CRUD 
operations ( Create, Read, U pdate, Delete (logically and not physically)) on 
clinical studies, but also on patients enrolled in these studies, and all exam-
inations to be performed on them. The focus was placed on the realization 
of a component to support administratively the management of prospective 
clinical studies, in which the objective is predefined before the start of the 
study, in a protocol document. 
For this component, the objectives have been achieved and the software 
actually offers the expecte<l fuuctious , with one excepti011 : the clients 
had expressed their enthusiasm for making a schedule for clinical studies 
containing the examinations of all patients enrolled in a study. This schedule 
should provide different views for the users to have an overview of the daily, 
weekly, or monthly examinations of the patients related to a clinical study in 























company blocked the development of the task, delaying its implementation in 
the coming months. 
Therefore, the persans retrieving the project in Mims and in UNamur will 
iuitially pursue the <levelopmeut of this task in or<ler to fiualize the first com-
ponent which support the administrative management of clinical studies in 
Belgian hospitals . 
2 Scientific analysis 
During the internship, we were interested in prospective clinical studies, i.e. 
the studies for which a protocol was predetermined before the establishment 
of the study, with a clear aud specific objective. However , there exists other 
types of studies that are conducted both internally and externally to the 
hospitals, by medical researchers. These retrospective studies, which do not 
have a predefined objective, concern common diseases and the analysis of the 
data collected in previous studies . 
The second component of the project IFlec to incorporate in the module 
OP'Study will consist in an interactive tool for analysing patients data, based 
on data mining. To this end, it will be necessary to analyse all the data 
available about patients, not only in the OmniPro patient records but also in 
the related modules. 
Afler thü; analy8Ü,, two µrocluct8 mu8t be imµlemented. The firnt deliver-
able is a modelling system for the definition of clinical studies; it will be used 
ro euable au eu<l u8er to create a uew 8tudy au<l defme it8 characteri8tic8. 
The second deliverable must allow the modelling of patient records. This 
abstraction should defiue exactly what should be implemeuted iu a patient 
record to enable data analysis. 
Such a task obviously have risks, and require working in partnership to 
prevent incorrect modelling of patient records or clinical studies. Therefore, 
UNamur continues to work with the company MIMS and the hospital of 
Mont-Godinne for this second component module. 
T he final step is to develop a tool for analysing data from the patient 
records, based on the demands of the doctors collected earlier. The tool will 























plains the observations of the study. It will have to identify, based on covari-
ance, factors that are not statistically independent, and model their addiction. 
Once the algorithms established principle, we study the scalability for large 
volumes of data. 
3 CDISC 
The process for the submission of clinical studies data through CDISC 
standardti contiists in simple tabular fileti, with a cleticription file for the 
relationships between these datasets. 
This technique is interesting but is not very conclusive in our research for 
a protocol for the subrnissiou of data to sponsors. Although created files are 
machine-readable, and also human-readable, they nevertheless remain very 
customized for each type of study. 
Basically, we wanted to find a complete and generic protocol to transfer 
medical data, but the research did not bring the expected answers. We 
certainly can reuse the syntax and semantics for the files to submit , but this 
solution propose<l by CDISC is too specific au<l persouali7,e<l. It could be 
interesting to reuse their structures, after generalization, and to find a transfer 
protocol for such structures. The organization did not bring a complete 
solution to find such a suitable protocol for all types of data related to clinical 
studies. 
It might be interesting to look to another organization to find a better and 
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1 Database SQL code 
1 create table STU_COMITE_ETHIQUE ( 
2 NUMCE NUMBER(19) not null, 
3 NOM_COMITE_ETHIQUE varchar2(60) 





DTECRE DATE default sysdate, 





9 ROWVERSION NUMBER(19) DEFAULT O NOT NULL, 
10 constraint PK_STU_COMITE_ETHIQUE primary key (NUMCE) USING INDEX 
TABLESPACE "MIMS_INDEX" ENABLE 
11 ) TABLESPACE "MIMS_DATA"; 
12 
13 create table STU_CRITERE_INCL_EXCL ( 
14 NUMCRI NUMBER(19) not null, 
15 NOM_CRITERE varchar2(200) not null, 
16 NUMETU NUMBER(19) not null, 
17 INCL_EXCL NUMBER(1) default O not null, 
18 DELETED NUMBER(l) default O not null, 
19 DTECRE DATE default sysdate, 
20 DTEMOD DATE default sysdate, 
21 NUMUSERCRE NUMBER(19), 
22 NUMUSERMOD NUMBER(19), 
23 ROWVERSIDN NUMBER(19) DEFAULT O NOT NULL, 
24 constraint I_STU_CRITERE_INCL_EXCL_NOM unique (NOM_CRITERE, NUMETU) 
USING INDEX TABLESPACE "MIMS_INDEX" ENABLE, 
25 constraint PK_STU_CRITERE_INCL_EXCL primary key (NUMCRI) USING INDEX 
TABLESPACE "MIMS_INDEX" ENABLE 
26 ) TABLESPACE "MIMS_DATA"; 
27 
28 create table STU_ETUDE ( 
29 NUMETU NUMBER(19) not null, 
30 NUM_EUDRACT varchar2(60) not null, 
31 NUM_ETUDE_CEC varchar2(60) not null, 
32 NOM_COURT varchar2(100) not null, 
33 NOM_COMPLET varchar2(200) not null, 





















35 NBR_PATIENTS NUMBER(4), 
36 OUVERTURE_RECRUTEMENT date, 
31 FERMETURE_RECRUTEMENT date, 
38 INTERVENTIONNELLE NUMBER(l) default O not null, 
39 OBJECTIF varchar2(5OO) not null, 
40 FIRME varchar2(1OO) not null, 
41 PERSONNE_CONTACT varchar2(1OO) not null, 
42 NUMORC NUMBER(19) not null, 
43 NUMSTE NUMBER(19) not null, 
44 NUMSERVICE NUMBER(19) not null, 
45 NUMCE NUMBER(19) not null, 
46 DELETED NUMBER(l) default O not null, 
47 DTECRE DATE default sysdate, 
48 DTEMOD DATE default sysdate, 
49 NUMUSERCRE NUMBER(19), 
50 NUMUSERMOD NUMBER(19), 
51 ROWVERSION NUMBER(19) DEFAULT O NOT NULL, 
52 constraint I_STU_ETUDE_EUDRACT unique (NUM_EUDRACT) USING INDEX 
TABLESPACE "MIMS_INDEX" ENABLE, 
53 constraint PK_STU_ETUDE primary key (NUMETU) USING INDEX TABLESPACE 
"MIMS_INDEX" ENABLE 
54 ) TABLESPACE "MIMS_DATA"; 
55 
56 create table STU_EXAMEN ( 
57 NUMEXA NUMBER(19) not null , 
58 NOM_EXAM varchar2(12O) not null, 
59 NUMPERS NUMBER(19) not null, 
60 EXAM_DATE date not null, 
61 KIT_LABO NUMBER(l) default O not null, 
62 NUMPAT NUMBER(19) not null, 
63 NUMSERVICE NUMBER(19) not null, 





DTECRE DATE default sysdate, 
DTEMOD DATE default sysdate, 
NUMUSERCRE NUMBER(19), 
NUMUSERMOD NUMBER(19), 
69 ROWVERSION NUMBER(19) DEFAULT O NOT NULL, 
70 constraint PK_STU_EXAMEN primary key (NUMEXA) USING INDEX TABLESPACE 
"MIMS_INDEX" ENABLE 
11 ) TABLESPACE "MIMS_DATA"; 
72 
13 create table STU_INVESTIGATEUR_AIDE ( 
74 NUMINV NUMBER(19) not null, 
75 NUMETU NUMBER(19) not null, 
76 INVEST_AIDE NUMBER(l) default O not null, 
11 NUMPERS NUMBER(19) not null, 
78 DELETED NUMBER(l) default O not null, 
19 DTECRE DATE default sysdate, 
80 DTEMOD DATE default sysdate, 
81 NUMUSERCRE NUMBER(19), 
82 NUMUSERMOD NUMBER(19), 
83 ROWVERSION NUMBER(19) DEFAULT O NOT NULL, 
84 constraint I_STU_INVEST_CRCM_INVEST unique (NUMPERS, NUMETU) USING 
INDEX TABLESPACE "MIMS_INDEX" ENABLE, 
85 constraint PK_STU_INVESTIGATEUR_CRCM primary key (NUMINV) USING 
INDEX TABLESPACE "MIMS_INDEX" ENABLE 























88 create table STU_ORC ( 
89 NUMORC NUMBER(19) not null, 
90 NOM_ORC varchar2(60) not null, 
91 DELETED NUMBER(1) default O not null, 
92 DTECRE DATE default sysdate, 
93 DTEMOD DATE default sysdate, 
94 NUMUSERCRE NUMBER(19), 
95 NUMUSERMOD NUMBER(19), 
9û ROWVERSION NUMBER(19) DEFAULT O NOT NULL, 
97 constraint PK_STU_ORG_RECH_CLINIQUE primary key (NUMORC) USING INDEX 
TABLESPACE "MIMS_INDEX" ENABLE 
98 ) TABLESPACE "MIMS_DATA"; 
99 
100 create table STU_PATIENT_ETUDE ( 
101 NUMPAT NUMBER(19) not null, 
102 NUMPATMIMS NUMBER(10) not null, 
103 DATE_CDNSENTEMENT date, 
104 DATE_RANDOMISATION date, 
105 DATE_DEBUT_SCREENING date, 
106 DATE_FIN_SCREENING date, 
101 DATE_DEBUT_TRAITEMENT date, 
108 DATE_FIN_ TRAITEMENT date, 
109 DATE_FIN_SUIVI date, 
110 NUMSTP NUMBER(19) not null, 
111 NUMETU NUMBER(19) not null, 
112 DELETED NUMBER(1) default O not null, 
113 DTECRE DATE defaul t sysdate, 
114 DTEMOD DATE defaul t sysdate, 
115 NUMUSERCRE NUMBER(19), 
116 NUMUSERMOD NUMBER(19), 
1 11 ROWVERSION NUMBER(19) DEFAULT O NOT NULL, 
118 NUMPATMIMS number(10) not null, 
119 constraint PK_STU_PATIENT_ETUDE primary key (NUMPAT) USING INDEX 
TABLESPACE "MIMS_INDEX" ENABLE 
120 ) TABLESPACE "MIMS_DATA"; 
121 
122 create table STU_STATUT_ETUDE ( 
123 NUMSTE NUMBER(19) not null, 
124 STATUT varchar2(60) not null, 
125 DELETED NUMBER (1) def aul t O not null , 
126 DTECRE DATE default sysdate, 
121 DTEMOD DATE default sysdate, 
128 NUMUSERCRE NUMBER(19), 
129 NUMUSERMOD NUMBER(19), 
130 ROWVERSIDN NUMBER(19) DEFAULT O NOT NULL, 
131 constraint PK_STU_STATUT_ETUDE primary key (NUMSTE) USING INDEX 
TABLESPACE "MIMS_INDEX" ENABLE 
132 ) TABLESPACE "MIMS_DATA"; 
133 
134 create table STU_STATUT_PATIENT ( 
135 NUMSTP NUMBER(19) not null, 
136 STATUT varchar2(60) not null, 




DTECRE DATE default sysdate, 






















14 1 NUMUSERMOD NUMBER(19), 
142 ROWVERSION NUMBER(19) DEFAULT O NOT NULL, 
143 constraint PK_STU_STATUT_PATIENT primary key (NUMSTP) USING INDEX 
TABLESPACE "MIMS_INDEX" ENABLE 
144 ) TABLESPACE "MIMS_DATA"; 
145 
146 create table STU_TRAITEMENT ( 
147 NUMTRT NUMBER(19) not null, 
148 NUMETU NUMBER(19) not null, 
149 NUMHIS number(1O) not null, 
150 DELETED NUMBER(l) default O not null, 
151 DTECRE DATE default sysdate, 
152 DTEMOD DATE default sysdate, 
153 NUMUSERCRE NUMBER(19), 
154 NUMUSERMOD NUMBER(19), 
155 ROWVERSIDN NUMBER(19) DEFAULT O NOT NULL, 
156 constraint I_STU_TRAITEMENT_NUMETUDE unique (NUMETU, NUMHIS) USING 
INDEX TABLESPACE "MIMS_INDEX" ENABLE, 
151 constraint PK_STU_TRAITEMENT primary key (NUMTRT) USING INDEX 
TABLESPACE "MIMS_INDEX" ENABLE 
158 ) TABLESPACE "MIMS_DATA"; 
159 
160 
161 alter table STU_CRITERE_INCL_EXCL add constraint EQU_INCLU_ETUDE_FK 
162 foreign key (NUMETU) 
163 ref erences STU _ETUDE; 
164 
165 alter table STU_ETUDE add constraint REF_ETUDE_ORGAN_FK 
166 foreign key (NUMORC) 
161 ref erences STU _ ORC; 
168 
159 alter table STU_ETUDE add constraint REF_ETUDE_STATU_FK 
110 foreign key (NUMSTE) 
111 references STU_STATUT_ETUDE; 
172 
113 alter table STU_ETUDE add constraint REF_ETUDE_COMIT_FK 
114 foreign key (NUMCE) 
1n references STU_COMITE_ETHIQUE; 
176 
111 alter table STU_ETUDE add constraint REF_ETUDE_PERSONNES_FK 
118 foreign key (NUMSERVICE) 
119 ref erences PERSONNES; 
180 
181 alter table STU_EXAMEN add constraint REF_EXAME_PATIE_FK 
182 foreign key (NUMPAT) 
183 ref erences STU _PA TIENT _ETUDE; 
184 
185 alter table STU_EXAMEN add constraint REF_EXAME_PERSONNES_FK 
186 foreign key (NUMPERS) 
181 ref erences PERSONNES; 
188 
189 alter table STU_EXAMEN add constraint REF_EXAME_PERSONNES_FK 
190 foreign key (NUMSERVICE) 
191 references PERSONNES; 
192 
193 

























foreign key (NUMETU) 
references STU_ETUDE; 




foreign key (NUMPERS) 
references PERSONNES; 
202 alter table STU_PATIENT_ETUDE add constraint REF_PATIE_STATU_FK 
203 foreign key (NUMSTP) 
204 references STU_STATUT_PATIENT; 
205 
206 alter table STU_PATIENT_ETUDE add constraint REF_PATIE_PATIENTS_FK 
201 foreign key (NUMPATMIMS) 
208 references PATIENTS; 
209 
210 alter table STU_PATIENT_ETUDE add constraint REF_PATIE_ETUDE_FK 
211 foreign key (NUMETU) 
212 references STU_ETUDE; 
2 13 
214 alter table STU_TRAITEMENT add constraint EQU_TRAIT_ETUDE_FK 
21s f oreign key (NUMETU) 
215 references STU_ETUDE ; 
217 
218 alter table STU_TRAITEMENT add constraint EQU_TRAIT_ETUDE_FK 
219 foreign key (NUMHIS) 
220 references MEDICATION; 
221 
222 alter table STU_PATIENT_ETUDE_TERMINEE add constraint REF_PET_ETUDE_FK 
223 foreign key (NUMETU) 
224 ref erences STU _ETUDE; 
225 
226 alter table STU_PATIENT_ETUDE_TERMINEE add constraint REF_PET_PATETUDE_FK 
227 
228 
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2.6 Menu modification of patient description 
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Figure 7.7: Menu of OP 'Study for the modification of examination description 
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Menu Principal 
Examen: 26 - Nom: Scanner thorax - Mëdecm responsable: GRAUX Carlos - Service: Radio & Scanner - Date: 16/1/2014 a 16h0 
Num examen 
Patient : 24 - Nom : TOCQUIN - Prénom: JENNY - Age : 51 
Nom Scanner thorax Autres examens du pat,ent TOCQUIN JENNY 
Médecin · GRAUX Carlos 
Service Radio & Scanner - ·- · . 
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2 .12 Menu : examinations bound to a patient in a clin-
ical study 
Figure 7.12: Menu of OP 'Study for the examinations bound to a patient en-
rolled in a clinical study 
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